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 ABSTRACT 
Pancreatic ductal adenocarcinoma (PDAC) is the deadliest of the common cancers, 
with a dismal prognosis attributed in part to late diagnosis in the majority of patients. 
Diagnosing early stage increases the likelihood of eligibility for surgical resection, 
currently the only available method of cure. In this thesis I have aimed to identify 
serum biomarkers for the diagnosis of PDAC, as a potential means of screening for 
the disease in a minimally-invasive manner. 
The glycoprotein tenascin C (TNC) was identified as a potential diagnostic 
biomarker in PDAC patient sera compared to patients with chronic pancreatitis (CP), 
a finding that was subsequently validated in an independent cohort of samples. As a 
benign inflammatory disease of the pancreas, pancreatitis commonly presents 
concurrently with PDAC making biomarkers that can distinguish the two a rarity. In 
attempting to identify the cause of increased circulating TNC in PDAC, in situ 
hybridisation performed on PDAC and CP tissue specimens identified tumour cells 
as a source of TNC, producing and secreting the protein into the surrounding stroma. 
Tissue microarray (TMA) analysis revealed stromal TNC was more common in 
PDAC patients than in CP, consistent with the pattern in sera. However, when 
available serum samples were matched to the tissue no direct relationship was found. 
Biomarker discovery work performed by other members of our group identified 
serum thrombospondin-1 (TSP-1) as a promising candidate biomarker for early 
diagnosis, decreased in sera collected up to 24 months prior to PDAC diagnosis. This 
observation was validated using multiple reaction monitoring, a relatively novel mass 
spectrometry-based method. Presented here are immunoassay results confirming the 
MRM data, along with serum analysis collected from a genetically engineered mouse 
model for PDAC suggesting that decreased TSP-1 levels may occur when PDAC is 
fully developed rather than at a preneoplastic stage. 
Finally, in light of the lack of correlation between circulating and stromal TNC, the 
possibility was considered that TMAs may not be sufficient for quantifying stromal 
expression in PDAC. A TMA was tested as a means of quantifying components of 
the PDAC stroma, and revealed that prognostic analyses yielded variable results 
depending on what depth of the TMA was analysed. This suggests that caution 
should be taken when applying this technique to such a heterogeneous disease. 
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1 INTRODUCTION 
 
The term ‘cancer’ is used to describe a number of complex diseases, all characterised 
by abnormal and uncontrolled cell proliferation in different organs of the body1,2. 
Hanahan and Weinberg have proposed ten hallmarks and enabling characteristics 
common to all cancers, namely: sustaining proliferative signalling, evading growth 
suppressors, activating invasion and metastasis, enabling replicative immortality, 
inducing angiogenesis, resisting cell death, evading immune destruction and 
regulating cellular epigenetics, all enabled by genome instability and mutation, and 
tumour-promoting inflammation2. These factors are the result of a complex 
environment within the tumour, where normal cells comprising the stroma are 
recruited amid a network of crosstalk signalling. Such interactions are thought to 
facilitate the invasive and proliferative properties characteristic of tumour cells. 
In 2011, cancer was ranked second on a list of leading causes of death in the United 
States3. Pancreatic cancer, the most prevalent form of which is pancreatic ductal 
adenocarcinoma (PDAC), is the most lethal common cancer, with a five-year 
survival of approximately 5%3–6. Currently it is the fourth leading cause of cancer-
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related death, but little improvement in survival rates has been made over the past 
few decades, and PDAC is projected to become the second leading cause by 20303,7. 
This dismal prognosis is attributed to the aggressive nature of the disease, its 
resistance to systemic therapy and late stage at diagnosis5. Early stage PDAC is 
typically asymptomatic, with advanced disease presenting symptoms such as weight 
loss, obstructed jaundice, abdominal pain, fatigue and anorexia4–6. Consequently, 
only approximately 20% of diagnosed patients are eligible for surgical resection, 
presently the only available method of cure5,8,9. 
Patients who undergo resection followed by adjuvant chemotherapy have an 
improved five-year survival of approximately 25%10–14. Surgery alone has poorer 
outcome, with 6 months of treatment with gemcitabine or fluorouracil (5FU) 
demonstrating a significant survival benefit11,12,14. Chemotherapy also confers a 
small survival benefit in patients with locally advanced or metastatic disease, with 
FOLFIRINOX (fluorouracil, irinotecan, oxaliplatin, leucovorin) or gemcitabine plus 
nab-paclitaxel comprising the current standard treatment in patients with good 
performance status5,15–18. 
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1.1 The biology of pancreatic cancer 
One of the characteristic features of PDAC transformation is a point mutation in the 
KRAS2 oncogene, occurring in ~90% of cases19–21. The production of constitutively 
active Ras protein drives cell cycle progression and survival, with these mutations 
reported in the most common PDAC precursor lesions, defined as pancreatic 
intraepithelial neoplasm (PanIN)21–24. KRAS mutations have also been identified in 
intraductal papillary mucinous neoplasms (IPMNs), another precursor lesion for 
PDAC5,25,26. The conventional model of disease progression begins with the 
formation of dysplastic PanIN lesions, with low to high dysplasia graded on a scale 
from 1-3, progressing to invasive carcinoma5,23,26.  
PanIN-1 lesions have been detected in non-diseased pancreata, increasing in 
prevalence with age, while higher grade lesions have been reported either adjacent to 
tumour or in individuals at a higher risk of developing PDAC5,27. Progression is 
driven by the accumulation of mutations, in particular inactivating mutations of 
tumour suppression genes, and disruptive epigenetic silencing through methylation 
of CpG islands5,21,24. The most commonly affected genes include p53, CDKN2A and 
SMAD4, the inactivation of which occur with increasing frequency in higher grade 
PanIN lesions5,21,28.  
Mutational analyses of established tumours indicate genomic instability is a key 
characteristic of PDAC, with heterogeneous clonal populations identified within 
tumours and metastases28–32. A recent whole-genome analysis of 100 PDAC tumours 
identified 5424 genes with non-silent mutations, while a seminal study that analysed 
24 tumours  reported an average of 63 genetic alterations per tumour, which could be 
broadly classified into 12 functionally-relevant signalling pathways29,32. This 
Chapter 1: Introduction 
                     23 
heterogeneity of PDAC tumour cells provides one explanation for the disease’s 
resistance to therapy, with the complex PDAC microenvironment also considered to 
be a crucial factor, making it the subject of intense study for the past decade. 
1.2 The pancreatic cancer microenvironment 
A notable feature of PDAC among other solid tumours is a particularly pronounced 
stromal compartment (Figure 1-1), with relatively poor vascularity33,34. The tissue 
microenvironment consists of a complex assembly of extracellular matrix, 
matricellular and soluble proteins, immune cells, fibroblasts and blood vessels 
(Figure 1-2)33–35.  
1.2.1 Inflammatory cells and PDAC  
Research over the past two decades has provided a wealth of evidence suggesting 
inflammatory cells assist tumour development rather than hinder it35,36. An obvious 
example of this phenomenon is found in PDAC with the higher incidence of cancer 
among patients with the inflammatory condition chronic pancreatitis (CP)37,38.  In 
genetically engineered mouse models (GEMMs) with conditional activating 
mutations of the Kras oncogene, cerulean-induced pancreatitis has been reported to 
accelerate the formation of PDAC39–41.  
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Figure 1-2. Diagram illustrating the components of the pancreas tissue microenvironment. 
Abbreviations: PanIN – pancreatic intraepithelial neoplasm, PDAC – pancreatic ductal 
adenocarcinoma. Figure adapted from Evans and Costello, 201235.  
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Figure 1-1. Haematoxylin and eosin stain displaying the PDAC 
microenvironment.  PDAC is characterised by a prominent desmoplastic stroma, 
indicated by black arrowheads. Inset is an example of PDAC tumour cells with a 
ductal phenotype (white arrowheads). Scale bar=100µm. 
 
Chapter 1: Introduction 
                     25 
Cell infiltrates from the innate and adaptive immune systems have been observed in 
many tumour types and have been linked to prognostic outcome and response to 
treatment35,36,42,42,43. Consequently, the need for tumours to escape the immune 
response and hijack inflammatory components to foster growth and progression have 
been recognised as key characteristics of cancer2. The complexity of the role of 
immune cells in cancer has led to their intense study over the past two decades, 
including in relation to PDAC34–36. 
1.2.1.1 Mast cells 
Several components of the immune system have been identified as promoters of 
PDAC cell growth and invasion. Mast cells play a key role in immune responses to 
microbial infection, and are thought to play a role in tissue remodelling and repair, 
tumour repression and tumour growth44. They express the receptor for stem cell 
factor (KIT) and are thought to be recruited and activated by tumour-derived stem 
cell factor, secreting inflammatory factors such as interleukin-6 (IL-6), tumour 
necrosis factor-α (TNF-α)and vascular endothelial growth factor (VEGF)45. They can 
also downregulate the immune response to tumours through secretion of 
immunosuppressive cytokines, such as IL-10, and by favouring expansion and 
activation of regulatory T (Treg) cells to promote immune tolerance45. 
A high influx of mast cells has been reported in the tumours of a mutant K-Ras 
(KRasG12V) mouse model for PDAC, noting an even distribution of mast cells in CP 
and PanIN lesions but a focal accumulation in tumours along the invasive front46. 
The infiltration in CP and PanIN lesions suggests that mast cell recruitment occurs 
early in the development of PDAC, and is consistent with the concept of 
inflammation potentiating neoplasia. Chang et al. grew orthotopic pancreatic 
tumours in mast cell-deficient (Kit-/-) mice and observed significantly reduced 
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tumour growth and improved survival times compared to control mice. They 
corroborated this finding in human tissues, noting that higher mast cell infiltration 
corresponded with poor outcome and consequently confirmed a trend observed in a 
previous study46,47. Similar work examining mast cell abundance in 103 patients with 
PDAC also noted a significant survival benefit to low cell counts in the cancerous 
border with normal tissue48. 
In a recent study by Schönhuber and colleagues, a dual-recombinase system for use 
in GEMMs was developed as a means of enabling secondary genetic manipulation in 
PDAC49. As a proof of concept, they crossed a mutant-KRas line with mast cell-
deficient Cpa3Cre/+ mice, thought to avoid a problem in Kit-deficient mice where 
non-immune components are altered, and observed PDAC development in mice at 12 
months of age despite the complete absence of mast cells, suggesting that mast cells 
are dispensable for formation of the disease49,50. Given the results of the studies 
linking mast cell abundance with prognosis, it is possible that mast cells may not be 
essential for PDAC formation but can still assist in its development, thus providing 
further evidence of the complexity of the role of the immune system in PDAC. 
1.2.1.2 Myeloid-derived suppressor cells 
Myeloid-derived suppressor cells (MDSCs) are immature myeloid cells, thought to 
enhance tumour growth by suppressing components of the innate and adaptive 
immune system51,52. They are comprised of two main subsets: CD14+ monocytic and 
CD15+ granulocytic subpopulations53. MDSCs can actively suppress host immunity 
by inhibiting T cell activation and migration, expanding Treg abundance and 
inhibiting natural killer (NK) cells53,54. 
An analysis of a KRasG12D GEMM  revealed a slight elevation of MDSCs in PanIN 
lesions, with a more pronounced increase in PDAC55. Clark et al. observed that 
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MDSCs accumulated around periductal areas and stroma, accompanied by a 
corresponding lack of CD8+ cytotoxic T cells55. Two separate GEMM studies 
identified tumour cells as a source of granulocyte macrophage colony-stimulating 
factor (GM-CSF), required for the recruitment of MDSCs, and noted that inhibiting 
GM-CSF inhibited tumour growth in a CD8+ T cell-dependent manner56,57. These 
findings were supported by Stromnes et al., who demonstrated that depleting 
granulocytic MDSCs in a GEMM increased intratumoral accumulation of activated 
CD8+ T cells and apoptosis of tumour epithelial cells58. Interestingly, they also 
observed stromal remodelling in their model, noting decreased extracellular matrix 
and an increased number of patent blood vessels. 
 
1.2.1.3 Tumour associated macrophages 
Under normal circumstances, macrophages fight infection and facilitate wound 
healing, localising to sites of inflammation where they mediate the inflammatory 
response through the release of cytokines and growth factors59. They are commonly 
classified into two extreme phenotypes, pro-inflammatory M1 or anti-inflammatory 
M2, though in reality this distinction is unlikely to be discrete as most fall along a 
continuum53,60,61. It is thought that M1 macrophages facilitate tumour cell death, 
while M2 macrophages enhance tumour progression53,60. 
A study by Kurahara et al. supports this concept, reporting that higher numbers of 
M2 macrophages on the tumour invasive front was associated with poorer overall 
survival in PDAC patients62. They also noted that M2 abundance correlated with a 
high incidence of lymph node metastasis, suggesting that histological analyses of the 
microenvironment may be clinically informative for other features of the disease. 
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An analysis of mutant KRasG12D mice has identified a potential mechanism by which 
macrophages enhance PDAC development. Lesina et al. identified Stat3 activation as 
an essential step for PanIN to progress to PDAC, mediated by IL-6 secreted 
primarily by macrophages63. A recent study also suggests macrophages may 
contribute to resistance to conventional chemotherapy, demonstrating a mechanism 
whereby tumour associated macrophages induce the upregulation of cytidine 
deaminse (CDA) in tumour cells, a metabolising enzyme that subsequently reduced 
the sensitivity of the cells to the drug gemcitabine64. 
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1.2.1.4 T cells 
T lymphocyte infiltrations have been reported in human and murine PDAC tissue 
specimens, with several studies focusing on the function of CD4+ FoxP3+ Tregs55,65–
67. Tregs, like MDSCs, demonstrate an immunosuppressive phenotype68. In PDAC 
patients, elevated circulating Tregs have been found in the peripheral blood 
compared to healthy controls, and correlated with MDSC abundance66. Greater 
numbers of Tregs have also been observed in PDAC stroma than in non-neoplastic 
inflammatory pancreatic tissue, and were associated with a poorer prognosis67. The 
prevalence of Tregs was found to increase with grade of PanIN lesions up to invasive 
ductal carcinoma, with a corresponding decrease in CD8+ cytotoxic T cell 
infiltration67. 
T helper (Th) cells have also been studied in the context of PDAC35. Th cells activate 
cells of the innate immune system, assist B cells and CD8+ cytotoxic T cells, and 
facilitate wound repair69. They can be classified into several subsets, including Th1 
cells that can induce microbial elimination and Th2 cells that are thought to mediate 
helminth immunity69. 
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Both Th1 and Th2 cells have been identified in human PDAC, though skewed in 
both number and activity towards the Th2 subset70. A subsequent study supported 
this observation, and demonstrated that an increased ratio of tissue Th2:Th1 cells was 
independently associated with poor prognosis in PDAC patients71. Recently, a study 
in KRasG12D mice has implicated Th cells in a mechanism of early neoplastic 
development. McAllister et al. observed IL-17-secreting Th17 cells were recruited to 
the pancreas in response to inflammation, and established that IL-17 overexpression 
could accelerate PanIN initiation and progression while IL-17 inhibition resulted in 
abrogated PanIN formation72. These results suggest different subsets of Th cells may 
have functional prominence at different stages of the development of PDAC. 
1.2.2 Desmoplastic stroma 
The dense desmoplastic milieu characteristic of PDAC has been studied extensively 
over the past decade, as there has been particular interest in developing anti-stromal 
therapies as an approach to enhancing chemotherapeutic delivery33,34. The 
extracellular matrix, consisting of collagen, hyaluronic acid (HA), proteoglycans, 
fibronectin and other matricellular proteins and enzymes, is thought to originate from 
activated myofibroblasts, commonly termed pancreatic stellate cells (PSCs)33,73,74. 
When isolated from tissue specimens, these cells inhabit a quiescent phenotype 
characterised by the accumulation of lipid droplets and are negative for α-smooth 
muscle actin (αSMA), but after ~48 hours adopt an activated phenotype, begin 
producing collagen type I and fibronectin and can be positively stained for 
αSMA73,74. 
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Studies utilising conditioned media (CM) and co-culture methods with activated 
myofibroblasts and PDAC cells have demonstrated cross-talk between the two 
populations. Conditioned media from PDAC cell lines has been shown to stimulate 
myofibroblast proliferation and the production of collagen I and fibronectin, while 
CM from activated myofibroblasts enhanced PDAC proliferation, migration and 
invasion75,76. Co-injection of mice with PDAC cells and myofibroblasts has been 
demonstrated to enhance tumour size, increase metastasis and resistance to 
chemotherapy, and suggests that tumour cells co-migrate with myofibroblasts to 
form metastases75–78. The latter observation is supported by a recent study examining 
desmoplasia in primary tumours and various sites of metastasis, concluding that both 
contain comparable levels of desmoplasia whilst also observing a greater mean 
αSMA+ area in metastases than in primary tumours79. 
It has been hypothesised that depleting the desmoplastic stroma may increase the 
vascular content of the tumour, facilitating the delivery of systemic therapies, which 
has guided investigators towards testing stromal inhibitors in GEMMs80. Mice 
expressing mutant KRas and p53 oncogenes (KPC) treated with IPI-926, a 
Smoothened (Smo) inhibitor to inhibit the hedgehog (Hh) pathway, had a marked 
increase in vascular perfusion and mean vessel density, and exhibited prolonged 
survival when combined with gemcitabine80. Subsequent studies targeting hyaluronic 
acid in KPC mice supported this finding, demonstrating improved blood vessel 
density and patency leading to increased intratumoral drug delivery and extended 
survival81,82. A phase I/II clinical trial assessing the effectiveness of HA inhibitors is 
still ongoing (NCT01453153), but unfortunately clinical trials testing Smo inhibitors 
have had to be halted due to increased mortality in the treatment arm34,83. 
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Recent studies depleting the stroma in GEMMs by pharmacological and genetic 
inhibition have also suggested this may be detrimental to survival84–86. Sonic 
hedgehog (Shh)- deleted mice with mutant KRas and floxed p53 had increased 
tumour vascularity but reduced survival compared to mice with wild type Shh, a 
finding corroborated by prolonged treatment with the Smo inhibitor IPI-92685. A 
separate study using three distinct GEMMs for PDAC also confirmed that Shh 
deletion and Smo inhibition accelerated tumour progression and reduced 
desmoplasia84. Similarly, a study using drug-inducible αSMA deletion to deplete 
myofibroblasts concluded that myofibroblast loss at early and late stages of PDAC 
development led to reduced survival, characterised by a greater prevalence of poorly-
differentiated tumours and significantly greater numbers of infiltrating Tregs86. 
These findings suggest that while the stroma may act as a barrier for drug treatment, 
caution should be taken when considering stromal depletion as a therapeutic 
approach. 
More optimistically, alternative approaches to targeting the stroma have been 
attempted with some success87,88. Sherman et al. demonstrated that targeting the 
vitamin D receptor (VDR) in cancer-associated fibroblasts led to a reprogramming of 
the stroma, reverting the fibroblasts to a quiescent phenotype and sensitising the 
tumour to gemcitabine to improve survival88. A study by Feig et al. observed that 
depleting fibroblast activation protein (FAP)-positive fibroblasts in KPC mice 
slowed tumour development but not when CD4+ and CD8+ T cells were 
pharmacologically depleted87. FAP+ cells were found to produce CXCL12 in the 
tumour, a chemokine that binds tumour cells and excludes T cells. Inhibition of its 
receptor, CXCR4, led to an accumulation of CD3+ T cells, and increased tumour cell 
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death after treatment with the immune checkpoint antagonist α-programmed cell 
death-ligand 1 (α-PD-L1)87. 
Though many of the studies examining the role of stroma in PDAC have utilised 
mouse models, several have also examined the prognostic impact of desmoplastic 
stroma in humans. An investigation measuring αSMA expression in tissue from 162 
patients enrolled in a randomised phase III clinical trial concluded that high αSMA 
expression was associated with reduced overall survival, though there was no 
association when only untreated patients were considered89. However, when patients 
were classified by stromal density determined by haematoxylin and eosin staining, a 
substantial survival benefit was seen in those with dense stroma in the untreated 
arm89. These findings supported a previous analysis of αSMA expression as a 
proportion of collagen in serial sections, termed the activated stroma index (ASI)90. 
Here, Erkan et al. found no significant association of αSMA expression with overall 
survival in 233 patients, and a modest survival benefit in patients with a high 
abundance of collagen. When patients were classified by ASI, those in the upper 
quartile had a significantly poorer prognosis than those in the lower quartile90. A 
more recent study by Özdemir et al. compared αSMA expression in 53 patients and 
found a significant positive association with overall survival in patients with high 
expression86. Different conclusions over whether an association exists between 
αSMA+ fibroblast abundance and survival may be due to differences in the scoring 
methods used, but data appear to be consistent in identifying dense desmoplastic 
stroma as prognostically favourable. This is consistent with the concept of 
desmoplastic stroma playing a protective role in PDAC, despite potentially 
presenting a barrier to therapeutic delivery.  
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Given the lack of success in clinical trials for drugs aimed at depleting the stroma, it 
is apparent that more work is needed to understand its role in PDAC. Promising 
results from stromal reprogramming and interference of immune cell-fibroblast 
crosstalk suggest that it can be exploited for therapeutic gain, but more understanding 
of the complex relationships between components of the tumour microenvironment 
is required. 
 
1.3 Diagnostic biomarkers for pancreatic cancer 
Presently the only hope for cure of PDAC is surgical resection accompanied by 
adjuvant (post-operative) chemotherapy, with clinical trials investigating the 
effectiveness of neoadjuvant (preoperative) therapy currently underway5. The 
resectability of the tumour is determined by its location and degree of progression, 
with clinical staging determined by TNM status (Table 1.1)6. Tumours at stage 0 
(Tis, N0, M0), stage IA (T1, N0, M0), stage IB (T2, N0, M0), stage IIA (T3, N0, 
M0) and stage IIB (T1-3, N1, M0) are considered resectable, with stage III (T4, any 
N, M0) considered borderline resectable if tumour encasement of the superior 
mesenteric artery (SMA) or coeliac axis is less than 180º, or if involvement is 
confined to the superior mesenteric vein or pulmonary vein6. Locally advanced stage 
III tumours are considered unresectable, where encasement of the SMA or coeliac 
arteries exceeds 180º or if venous involvement is unreconstructable, as are stage IV 
metastatic tumours (any T, any N, M1)6. 
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Table 1.1. TNM classification definitions for PDAC. 
  Definition 
T: 
Primary 
tumour 
TX 
T0 
Tis 
T1 
T2 
T3 
 
T4 
Primary tumour cannot be assessed 
No evidence of primary tumour 
Carcinoma in situ 
Tumour confined to pancreas, ≤ 2 cm largest dimension 
Tumour confined to pancreas, > 2 cm largest dimension 
Tumour extends beyond panceas, but no involvement of coeliac 
axis or superior mesenteric artery 
Tumour involves the coeliac axis or superior mesenteric artery 
 
N: 
Regional 
lymph node 
 
NX 
N0 
N1 
Regional lymph nodes cannot be assessed 
No regional lymph nodes 
Regional lymph node metastasis 
M: 
 
Distant 
metastases 
M0 
M1 
No distant metastasis 
Distant metastasis 
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With only ~20% of PDAC cases considered resectable or borderline resectable, there 
is an urgent need for methods of diagnosing patients at an earlier stage5,8,9. A study 
that used lineage labelling in a GEMM for PDAC discovered that epithelial-to-
mesenchymal transition (EMT) and dissemination of neoplastic cells occurred from 
as early a stage as PanIN formation91. The possibility of metastasis occurring early in 
the development of PDAC suggests that early intervention is required, and that there 
may be opportunities to diagnose the disease at an earlier stage than is currently 
achievable92. Given the urgency of this requirement for improving survival, 
numerous approaches have been undertaken to identify biomarkers for the diagnosis 
of PDAC. 
1.3.1 Protein biomarkers in the circulation 
The use of blood-borne biomarkers to screen for PDAC is an attractive proposition, 
as samples can be obtained in a minimally invasive manner and are already routinely 
handled by clinical laboratories. Challenges are posed when attempting to identify 
new biomarkers in blood-based samples however, as the concentration of analytes 
cover a large dynamic range, and low abundance proteins can easily be masked by 
highly abundant proteins such as albumin93. These difficulties, along with the 
challenge of huge environmental and genetic variation across subjects, have 
prevented researchers from identifying robust diagnostic biomarkers for PDAC. 
Currently the only serum biomarker routinely used for PDAC is the sialylated Lewis 
blood group antigen carbohydrate antigen 19-9 (CA19-9), informing assessments of 
disease recurrence and monitoring response to chemo- and radiotherapy94,95. It is 
currently considered to be unsuitable for screening, with a sensitivity and specificity 
for PDAC diagnosis of approximately 80%96. Moreover, CA19-9 is not produced in 
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the 5% of the population who are Lewisa-b- and is consequently uninformative for 
this group97. Given the lack of progress in identifying novel single biomarkers 
specific for PDAC, it is likely that a panel of biomarkers may need to be identified, 
to use in combination with CA19-9 or otherwise. Consequently, many studies have 
combined several markers to improve diagnostic sensitivity and specificity92. 
Brand et al. performed a multiplex analysis for 83 proteins on a large cohort of 
serum samples, comprised of 333 PDAC patients, 144 with benign pancreatic 
disorders (pancreatic cysts, chronic pancreatitis and acute pancreatitis) and 227 
healthy controls98. With their samples split into discovery and validation sets, they 
initially identified two panels of three markers that discriminated PDAC cases from 
healthy individuals and benign pancreatic disorders. Using receiver operator curves 
they identified a combination of CA19-9, intercellular adhesion molecule 1 (ICAM-
1) and osteoprotegerin (OPG) that distinguished PDAC cases with a maximum 
sensitivity and specificity of 88% and 90% respectively, yielding an area under the 
curve (AUC) of 0.93 in the discovery set, compared to 0.83 with CA19-9 alone. This 
panel was similarly accurate in the validation set, resulting in an AUC of 0.91. They 
also found that a panel combining CA19-9, carcinoembryonic antigen (CEA) and 
tissue inhibitor of metalloproteinases 1 (TIMP-1) could distinguish PDAC cases 
from benign disorders, though the improvement over CA19-9 alone was more 
modest (AUC=0.86 vs 0.82). Again, this panel performed with a similar degree of 
accuracy in the validation set (AUC=0.83)98. These findings are an example of how 
combining biomarkers can improve diagnostic performance, particularly over CA19-
9 alone, as well as demonstrating the increased difficulty of discriminating PDAC 
patients from benign pancreatic disorders compared to healthy subjects.   
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A similar study applying multiplex methods on a large serum cohort also 
demonstrated the effectiveness of biomarker combination, splitting a cohort of 248 
PDAC patients,114 healthy subjects and 102 CP patients into training and validation 
sets99. Park et al. identified a panel comprised of CA19-9, matrix metalloprotease 7 
(MMP-7) and cathepsin D could diagnose PDAC from all controls with an AUC of  
0.90 and 0.91 in the discovery and validation cohorts respectively99. Similar accuracy 
was obtained by Gold et al. using an assay for PAM4,  a monoclonal antibody, in 
combination with CA19-9 in a cohort of 298 PDAC patients, 79 healthy subjects, 
120 patients with benign pancreatic disorders and 99 non-pancreatic cancer 
patients100. ROC analysis yielded an AUC of 0.91 in distinguishing PDAC cases 
from benign disorders, and the same again for PDAC compared to CP patients. 
The results of these studies are encouraging, and suggest a diagnostic panel of 
proteins with close to 100% accuracy may one day be achievable. However, work 
conducted by our group and others has recently established that the presence of 
obstructive jaundice is a confounding factor in identifying circulating diagnostic 
biomarkers for PDAC in serum and plasma92,101–104. Tumours developing in the head 
of the pancreas, the most common site in PDAC, can obstruct the bile duct, making 
jaundice a common symptom among PDAC patients5,105. 
Tonack et al. used isobaric labelling in combination with tandem mass spectrometry 
to identify diagnostic proteins in sera from healthy subjects (n=29) and patients with 
PDAC (n=64), CP (n=48) and benign biliary obstruction caused by gallstones or 
liver disease (n=31)102. The observation was made that splitting PDAC cases 
according to jaundice status (total serum bilirubin> 20μmol/L) revealed reduced 
sensitivity in distinguishing PDAC patients without jaundice from benign disorders 
and healthy subjects. Correspondingly, specificity was also reduced in jaundiced 
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PDAC patients compared to patients with benign biliary obstruction102. A study by 
Nie et al. supported this conclusion, identifying a panel of serum glycoproteins that, 
in combination with CA19-9, had a diagnostic AUC of 0.96 for PDAC compared to 
CP patients, but only 0.74 when compared to patients with benign obstructive 
jaundice103. A separate study attempting to validate ICAM-1 and TIMP-1 in a cohort 
of serum samples from patients with CP, benign biliary obstruction, obstructed and 
non-obstructed PDAC and healthy controls (all n=20) observed that neither marker 
was significantly deregulated in PDAC patients with jaundice compared to those 
with benign jaundice106. Moreover, concentrations of both markers in PDAC patients 
without jaundice were not significantly different from those in CP patients, in 
contrast to previous studies106. Taken together, these studies suggest that a 
background of jaundice should always be considered when selecting PDAC patients 
to test for circulating biomarkers, and comparisons made with jaundiced patients of 
benign origin if possible. The lack of concordance of TIMP-1 and ICAM-1 
measurements with previous studies also demonstrates the importance of validation 
in independent cohorts, with confounding variables taken into account. 
Though cases are rarer, focusing biomarker analyses on early stage PDAC samples 
where the tumour is confined to the pancreas may avoid the confounding effects of 
jaundice. Pan et al. analysed a cohort of plasma from stage I-II PDAC and CP 
patients, as well as healthy subjects (all n=20), and discovered that combining 
gelsolin and lumican could discriminate PDAC cases from all control groups 
(AUC=0.94)107. They also demonstrated that the use of multiple reaction monitoring 
(MRM), a mass spectrometry-based method of quantification, gave comparable 
measurements to the more standard enzyme-linked immunosorbent assays (ELISAs) 
for TIMP-1 in plasma107. Makawita et al. also restricted their analysis of PDAC 
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patients to stage I-II cases (n=82), validating biomarkers they had previously 
identified in serum and comparing with healthy subjects (n=47), benign pancreatic 
disorders (CP and neoplasms, n=42) and non-pancreatic cancer patients (n=70)108. 
They identified a panel that could discriminate PDAC cases from all benign and 
healthy control groups (AUC=0.92), compared to CA19-9 alone (AUC=0.8). 
The studies discussed so far have used samples collected from diagnosed patients, 
and may have identified informative biomarkers for diagnosis in the clinic. They are 
also candidates for testing in pre-diagnostic cohorts of samples, to assess their 
suitability as a screening tool for vital early diagnoses. Unfortunately, such cohorts 
of samples from individuals collected prior to PDAC diagnosis are rare. To 
overcome this, studies have utilised blood from GEMMs collected at different stages 
of disease to identify potential candidates for early diagnosis109,110. 
Faca et al. used tandem mass spectrometry with isotopically labelled pooled plasma 
samples, collected from transgenic mice with mutant Kras and floxed Ink4a/Arf with 
developed PanIN lesions or PDAC alongside matched controls109. They identified a 
panel of proteins that was tested in human sera from PDAC (n=30) and CP (n=10) 
patients, alongside healthy controls (n=20), giving a diagnostic AUC of 0.96. 
Interestingly, they also tested a panel of five proteins found to be upregulated in mice 
with PanIN lesions in a set of pre-diagnostic human sera from the CARET study. 
Thirteen samples obtained between 7 and 13 months prior to PDAC diagnosis were 
analysed for this panel alongside matched controls, yielding an AUC of 0.82109. 
Though the sample size is low for a panel of five markers, these results suggest 
analysing samples GEMMs for comparison with human samples is a valid approach. 
A similar study conducted by Mirus and colleagues utilised an antibody microarray 
containing ~130 antibodies to analyse plasma from KPC mice at different stages of 
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disease progression, diagnosed with PanIN lesions alone or developed PDAC110. A 
simultaneous analysis of 87 PDAC samples collected up to 4 years prior to diagnosis, 
with matched controls, was also performed. Two proteins were identified as 
upregulated in both cohorts, and when combined with a third an AUC of 0.68 was 
achieved in the pre-diagnostic human samples. As expected, when the analysis was 
extended to a separate set of samples from diagnosed PDAC patients (n=24) and 
controls (n=24) the diagnostic accuracy was improved (AUC=0.86),110. The 
promising findings from these two studies raise the possibility that the use of 
GEMMs with pre-diagnostic human samples may be an effective method of 
identifying novel biomarkers for early diagnosis. 
Many of the studies mentioned so far have focused on proteins and glycoproteins 
present in the circulation, quantified with the use of mass spectrometry, multiplex 
assays, antibody arrays, immunoblotting and ELISAs. Alternative approaches  have 
also been undertaken, investigating cytokines and autoantibodies as potential PDAC 
biomarkers104,111–114. 
Zeh et al. demonstrated that cytokines are feasible biomarker candidates, using a 
panel of five cytokines to differentiate PDAC serum samples from CP patients and 
healthy controls, and improving upon CA19-9 alone111. A study by Shaw et al. 
measured 27 cytokines in sera from PDAC (n=127) and CP (n=49) patients, 
alongside benign obstructed jaundice patients (n=20) and healthy controls (n=45),104. 
After splitting the samples into training and validations set, panels of cytokines were 
identified that could be combined with serum CA19-9, yielding a diagnostic AUC of 
0.84 and 0.88 in the training and validation sets respectively when discriminating 
PDAC cases from benign controls104. 
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Recent studies have indicated that PDAC patients produce autoantibodies whose 
detection can distinguish cases from benign controls112–114. One study compared 
serum samples from 300 PDAC samples and 300 controls to identify several 
upregulated antibodies, though individually the AUC for each marker was relatively 
low113. Another group identified autoantibodies for serum phosphorylated enolase 
(ENOA1,2) as highly accurate biomarkers for PDAC (n=120) compared to healthy 
controls (n=40) and CP patients (n=46), with AUCs of 0.94 and 0.95 for advanced 
and resectable cancers versus all controls respectively112. This study was recently 
expanded to include autoantibodies for ezrin, identified in sera from KPC mice with 
PanIN lesions and PDAC as a potential early diagnostic marker114. Ezrin antibodies 
were confirmed to be significantly upregulated in human pre-diagnostic sera from the 
EPIC cohort (PDAC n=16, controls n=32) with a minimum time of 5 months prior to 
diagnosis. Combining ezrin autoantibodies with CA19-9 and antibodies for 
ENOA1,2 improved accuracy in a cohort of diagnosed samples, yielding an AUC of 
0.96 for PDAC patients (n=45) compared to benign subjects (n=48)114. These 
findings suggest the detection of autoantibodies for tumour-associated antigens may 
be an effective strategy for diagnosing PDAC. 
1.3.2 Protein biomarkers in urine 
While much of the focus on PDAC biomarkers has been towards those in the 
circulation, the identification of markers in other easily-accessible samples is equally 
important. A recent investigation by Radon et al. utilised a proteomic analysis of 
pooled urine samples obtained from patients with PDAC, CP and healthy controls 
(all n=6), separated by SDS-PAGE and analysed by tandem mass spectrometry115. 
Three proteins were identified, LYVE1, REG1A and TFF1, and selected for further 
analysis in a large multicentre cohort of urine samples (PDAC n=192, CP n=92, 
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healthy control n=87). After splitting samples into a training and validation set, ROC 
analysis of the three proteins combined revealed diagnostic AUC for PDAC from 
healthy controls of 0.89 and 0.92 in the training and validation sets, respectively. 
Similar diagnostic accuracy was achieved when only stage I-II cancers were 
considered, but was improved further by combination with plasma CA19-9 
measurements. Restricting the PDAC cases to stage I-IIA, for localised disease with 
no nodal involvement, resulted in an AUC for the panel of 0.97, compared to CA19-
9 alone with 0.84, where adding CA19-9 to the panel conferred no diagnostic 
improvement115. These promising results warrant further investigation as potential 
early diagnostic markers, and suggest that screening urine is a valid strategy in 
identifying diagnostic biomarkers for PDAC. 
1.3.3 MicroRNA markers in the circulation 
MicroRNAs (miRNAs) are small non-coding RNA molecules that make for 
attractive candidates as biomarkers due to remarkably high stability in the 
circulation116. Though the breadth of studies investigating miRNA biomarkers for 
PDAC is much smaller than for protein, several studies have identified potential 
candidates. An analysis of plasma samples from 36 PDAC patients and 30 healthy 
controls revealed miR-18a levels were significantly higher in cancer cases, with a 
diagnostic AUC of 0.94117. A larger study analysed serum and plasma from 80 
PDAC patients and 129 healthy subjects for U2 small nuclear RNA fragments 
(RNU2-1f), identified after detecting miR-1246 in mouse PDAC xenografts and 
determining RNU2-1f as the source of this miRNA sequence118. Though direct 
diagnostic AUC values for PDAC were not reported, a high degree of separation 
from healthy controls was observed118. A study conducted by Li et al. analysed sera 
from 45 PDAC patients, 32 healthy subjects and 11 patients with CP, and observed 
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greater levels of miR-200a and miR-200b in PDAC than healthy controls 
(AUC=0.86 and 0.85 respectively), but no differences between PDAC and CP119. 
The use of miRNAs for the diagnosis of PDAC may yet prove to be effective, and 
further analysis of larger cohorts that include benign pancreatic disorders is 
warranted. 
1.3.4 Circulatory exosomes as biomarkers for pancreatic cancer 
Exosomes are extracellular vesicles secreted by cells, containing proteins and nucleic 
acids. A recent study observed an abundance of exosomes expressing the cell surface 
proteoglycan glypican-1 (GPC1) in sera from patients with PDAC120. Samples from 
190 PDAC patients were compared with 100 healthy controls and 26 patients with 
benign pancreatic disorders, revealing all PDAC cases had greater numbers of 
GPC1+ exosomes than all of the control samples (AUC=1.0). This finding was 
replicated in an independent cohort of 56 PDAC, 6 benign pancreatic disorder 
patients and 20 healthy control samples (AUC=1.0). GPC1+ exosomes quantified in 
sera from a GEMM for PDAC revealed exosome numbers correlated with disease 
progression, with notable increases preceding visible formation of tumour masses as 
determined by magnetic resonance imaging (MRI)120. These findings are extremely 
promising, particularly if the exceptional diagnostic accuracy can be maintained 
when comparing with a larger cohort of benign pancreatic disorders. The correlation 
of GPC1+ exosome levels with disease burden in the mouse models suggest that this 
is a promising marker for testing in a pre-diagnostic sample cohort120. Even if these 
findings fail to be validated in independent cohorts, the measurement of exosomes 
with different surface markers to GPC1 may be warranted as an alternative approach 
to discovering diagnostic biomarkers for PDAC. 
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Much of the current research into pancreatic cancer, both in terms of therapy and for 
understanding the tumour biology, is focused on understanding the role of the 
stroma. Despite great progress in our understanding of the disease, survival rates 
have been slow to improve4–6. There is still an urgent need for methods of diagnosing 
PDAC at an early enough stage for resection, currently the only available option for 
cure. The use of genetically engineered mouse models has been invaluable in 
elucidating the role of components in the tumour microenvironment, and has enabled 
investigations into circulatory biomarkers at early stages of disease progression. 
Nevertheless, recent paradigm shifts in how to approach therapy targeting the stroma 
reveal more work is needed in understanding its complexity34. Similarly, studies 
investigating biomarkers using samples from pre-diagnostic cohorts are still 
relatively scarce, and we have yet to identify independently-validated early 
diagnostic markers  that can discriminate PDAC cases from benign controls92. 
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1.4 Hypotheses 
The hypotheses to test were: proteins in the circulation can be quantified for specific 
early diagnosis of pancreatic cancer. Secondly, that aberrant concentration of 
proteins in the sera relate to their expression in the pancreatic tissue 
microenvironment. 
1.5 Aims and objectives 
1. Identify serum biomarkers for the detection of pancreatic cancer. 
a. Quantify cancer-associated proteins in two cohorts of serum samples, 
one comprised of pre-diagnostic sera from PDAC patients and another 
of diagnosed patient samples with PDAC or benign pancreatic 
disorders. 
b. Test candidate proteins from this analysis, and others identified by 
members of the group, in an independent cohort of samples to verify 
their suitability as diagnostic biomarkers. 
2. Investigate protein biomarker expression in the pancreatic tissue 
microenvironment. 
a. Identify areas of protein expression in patient tissue specimens. 
b. Determine if protein levels in the circulation correspond with 
expression in tissue microarrays containing matched tissue specimens. 
3. Determine if tissue microarrays are suitable for quantifying components of 
the pancreatic cancer stroma. 
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2 DISCOVERY AND 
VALIDATION OF 
DIAGNOSTIC SERUM 
BIOMARKERS FOR 
PANCREATIC CANCER 
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2.1 Introduction 
2.1.1 Identification of promising diagnostic serum biomarkers for 
pancreatic cancer using a multiplex Luminex approach 
To identify protein biomarkers for the early diagnosis of PDAC in a disease-specific 
manner, a multi-analyte profile panel, the Human Oncology MAP (Myriad Rules-
Based Medicine; http://www.rulesbasedmedicine.com/), which enables the 
measurement of 101 target proteins in serum using Luminex technology was used 
(Table 2.1). Luminex xMAP technology relies on 5.6µm polystyrene microspheres 
stained with two fluorochromes to varying degrees, such that each microsphere set 
has a unique fluorescent signature detectable by excitation with a red diode laser121. 
This enables the mixing of multiple microsphere sets as each bead can still be 
uniquely identified by its fluorescent spectrum. By tagging microsphere sets with 
specific capture antibodies, the detection of each microsphere can be associated with 
a specific analyte. Once the antigens in the sera have bound to the microspheres, 
biotinylated detection antibodies are added followed by streptavidin-phycoerythrin as 
a third fluorochrome. Excitation of bound R-phycoerythrin is performed with a green 
yttrium aluminium garn (YAG) laser, concurrently with the red diode laser, for 
detection and quantification of bound protein per microsphere. Suspended 
microspheres are passed through the detection chamber in single file for discrete 
measurements of each bead, with thousands of beads read per second. These 
principles enable multiplex analysis of up to several analytes per reaction. 
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Table 2.1. Full list of Human OncologyMAP® v.1.0 proteins quantified by Myriad RBM 
Human OncologyMAP® v.1.0 
6Ckine  Aldose reductase  
Alpha-fetoprotein  Amphiregulin  
Angiogenin  Annexin A1  
B cell-activating factor  B lymphocyte chemoattractant  
Bcl-2-like protein 2  Betacellulin  
Cancer antigen 125  Cancer antigen 15-3  
Cancer antigen 19-9  Cancer antigen 72-4  
Carcinoembryonic antigen  Cathepsin D  
Cellular fibronectin  Collagen IV  
Endoglin  Endostatin  
Eotaxin-2  Epidermal growth factor  
Epidermal growth factor receptor  Epiregulin  
Epithelial cell adhesion molecule  Ezrin  
Fatty acid-binding protein, adipocyte  Fatty acid-binding protein, liver  
Fibroblast growth factor basic  Fibulin-1C  
Galectin-3  Gelsolin  
Glucose-6-phosphate isomerase  Glutamate-cysteine ligase regulatory subunit  
Glutathione S-transferase Mu 1  HE4  
Heparin-Binding EGF-Like Growth Factor  Hepatocyte  
Growth Factor  Hepatocyte growth factor receptor  
Hepsin  Human chorionic gonadotropin β  
Human epidermal growth factor receptor 2  Insulin-like growth factor-binding protein 1  
Insulin-like growth factor-binding protein 2  Insulin-like growth factor-binding protein 3  
Insulin-like growth factor binding protein 4  Insulin-like growth factor binding protein 5  
Insulin-like growth factor binding protein 6  Interferon gamma induced protein 10  
Interferon-inducible T-cell α chemoattractant Interleukin-2 receptor alpha  
Interleukin-6  Interleukin-6 receptor subunit β  
Kallikrein 5 Kallikrein-7  
Lactoylglutathione ly.ase  Latency-associated peptide of transforming growth factor β1  
Leptin  Macrophage inflammatory protein 3 β 
Macrophage migration inhibitory factor Macrophage-stimulating protein  
Maspin  Matrix metalloproteinase-2  
Mesothelin  MHC class I chain-related protein A  
Monocyte chemotactic protein 1  Monokine induced by gamma interferon 
Neuron-specific enolase  Neuropilin-1 
Neutrophil gelatinase-associated lipocalin  Nucleoside diphosphate kinase B  
Osteopontin  Osteoprotegerin 
Pepsinogen I  Peroxiredoxin-4  
Phosphoserine aminotransferase  Placenta growth factor  
Platelet-derived growth factor BB  Prostasin 
Protein S100-A4  Protein S100-A6  
Receptor tyrosine-protein kinase erbB-3  Squamous cell carcinoma antigen-1  
Stromal cell-derived factor-1  Tenascin C  
Tetranectin Thyroglobulin  
Tissue type plasminogen activator  Transforming growth factor α 
Tumor necrosis factor receptor I  Tyrosine kinase with ig and egf homology domains 2  
Urokinase-type plasminogen activator  Urokinase-type plasminogen activator receptor  
Vascular endothelial growth factor  Vascular endothelial growth factor B  
Vascular endothelial growth factor c  Vascular endothelial growth factor D 
Vascular endothelial growth factor receptor 1  Vascular endothelial growth factor receptor 2  
Vascular endothelial growth factor receptor 3  YKL-40 
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2.1.2 Choice of samples for analysis 
Two sets of human serum samples were selected for analysis. They were designed to 
accommodate the challenges posed in identifying diagnostic biomarkers for PDAC. 
Patients with obstructed jaundice from benign causes were included in the sample 
set, as the presence of biliary obstruction in patients with PDAC is a confounding 
factor in biomarker studies101,102,122,123. Similarly, existing biomarkers including 
CA19-9 have demonstrated poor specificity for PDAC when compared to patients 
with chronic pancreatitis123,124. Thus, chronic pancreatitis patients were selected to 
address the specificity of potential protein biomarkers for PDAC. Finally, in the past 
serum biomarker discovery programs have generally used samples from diagnosed 
patients, with the inherent risk that changes occurring prior to diagnosis are missed. 
To address this concern, a pre-diagnosis cohort was employed in collaboration with a 
group from University College London, led by Dr John Timms. The UK 
Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) was established by 
the University College London (UCL) Institute for Women’s Health as a randomised 
controlled trial following 202,638 post-menopausal, healthy women to assess the 
value of screening for ovarian cancer125. Upon recruitment a serum sample was 
taken, with 50,000 women also providing annual samples such that serial samples 
were available dating back up to eight years. In this cohort, 226 women went on to 
develop PDAC; as a result the biobank contained serum samples collected up to five 
years prior to the diagnosis of PDAC. This offered the opportunity to detect 
biomarkers with aberrant expression at time points prior to conventional clinical 
methods of diagnosis. 
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2.1.3 Logistic regression analysis for the identification of potential 
biomarkers of PDAC  
Logistic regression is a method of fitting a model with a dichotomous dependent 
variable, in this case PDAC diagnosis, using a set of independent variables126. This 
method can be paired with calculation of a receiver operating characteristic (ROC) 
curve, which plots the performance of a variable’s sensitivity, the ability to detect a 
true signal, against false positive detection (1-specificity) over a range of thresholds 
for that variable126. Measuring the area under the curve (AUC) allows for comparison 
of different markers’ performance in accurately classifying a dichotomous variable, 
with an AUC of 1 indicating perfect classification and 0.5 indicating no classification 
effect by the independent variable. 
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2.2 Samples and materials and methods 
2.2.1 University of Liverpool collection 
The University of Liverpool (UoL) collection consisted of serum taken from healthy 
subjects as well as from patients diagnosed with PDAC, chronic pancreatitis (CP) 
and benign diseases causing obstructive jaundice. All samples were collected at the 
Royal Liverpool University Hospital with ethical approval and patients and subjects 
participated with written informed consent. Serum was obtained from blood samples 
collected in Sarstedt Monovette tubes (Sarstedt Ltd., UK), left to clot at 4ºC for 15 
minutes before centrifugation at 800g for 10 minutes. The serum supernatant was 
then aliquoted and stored at -80ºC for future use. 
2.2.2 UKCTOCS collection 
Each pre-clinical PDAC case from the UKCTOCS collection was matched with a 
healthy control sample based on the same collection centre, collection date, and 
equivalent age as closely as possible. Thus, 45 PDAC samples with 45 matched 
controls were selected for this study. Initially, the samples were divided equally into 
five time groups: 0-6 months, 6-12 months, 1-2 years, 2-3 years and 3-4 years prior 
to diagnosis. However, subsequent histological review of patient data since the 
experiment was conducted revealed a small number of patients had been 
misclassified as PDAC and had incorrect dates of diagnosis. Misclassified samples 
were removed from the analysis and the time to diagnosis for the remaining samples 
was recalculated. For this reason, there is considerable disparity in the numbers of 
individuals per group in this analysis. 
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2.2.3 Myriad RBM multiplex protein quantification 
Serum samples from both sample cohorts were shipped for analysis to Myriad RBM 
located in Austin, Texas, where the analysis was undertaken. Using microspheres 
coupled with a capture-antibody sandwich approach enabled multiplex quantification 
of 101 proteins (Table 2.1). Briefly, each serum sample was pre-diluted and, in 96-
well hard-bottomed microtitre plates, 10µL was mixed with 5µL blocker and 5µL of 
mixed diluted capture-antibody microspheres. Standards and controls were also 
mixed accordingly with the microsphere mixture before plate incubation for 1 hour at 
room temperature. 10µL biotinylated detection antibody was added to each well 
before a further 1 hour incubation. A similar addition of 10µL streptavidin-
phycoerythrin per well followed, and was left to incubate again for 1 hour. A filter-
membrane microtitre plate was pre-wetted with 100µL wash buffer before aspiration 
using a vacuum manifold device. The contents of the hard-bottomed plates were 
transferred to the respective wells of the filter plate then vacuum-aspirated and 
washed twice with 100µL wash buffer. After the final wash a further 100µL wash 
buffer is added to each well before thorough mixing to resuspend the microspheres. 
The plated protein-bead conjugates were subsequently analysed with a Luminex 100 
Analyzer (Luminex, USA). For each protein analyte, a standard curve was fitted 
using known quantities of analyte on the same microtitre plate. Previously unknown 
concentrations of proteins in the serum samples were then calculated by comparing 
the median fluorescence intensity (MFI) for each analyte with its respective standard 
curve. Multiplication by the sample dilution factor then gives a final concentration of 
each protein for that sample. Myriad RBM defined the lower limit of quantification 
(LLOQ) as the concentration at which the coefficient of variation (CV) percentage 
equalled 30%. This was determined for each analyte by two-fold dilution of a 
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medium standard eight times, assaying in triplicate over three separate runs before 
calculating and plotting the CV against concentration. Samples whose measured 
concentration fell below the LLOQ were excluded from the analysis for that analyte. 
2.2.4 Serum protein measurement by enzyme-linked immunosorbent 
assay (ELISA)  
Commercially available enzyme-linked immunosorbent assay (ELISA) kits were 
purchased for IL-6Rβ (cat. no. DGP00, R&D Systems, UK), TNC (cat. no. 27767, 
IBL International, Japan) and PSAT (cat. no. CSB-EL018838HU, Cusabio, China). 
Each kit used sandwich immunoassay principles to quantify the protein of interest. 
Briefly, serum was diluted and added to antibody-coated 96-well plates then 
incubated so that antigen would bind to the base of the wells. This was followed by 
washing and addition of a horseradish peroxidase (HRP)-linked antibody, before 
further washing and the addition of tetramethylbenzidine (TMB) as a chromogen. 
TMB is converted by HRP to a coloured product such that the degree of colour 
change is proportional to the amount of bound antigen. Known quantities of the 
protein of interest were measured alongside the serum samples in order to generate a 
standard curve, against which the measured colour absorbance of the serum could be 
compared to calculate an exact protein concentration. Assays were all performed to 
manufacturer’s instructions, with absorbance measurements performed using a 
Thermo Multiskan Ex (Thermo Fisher Scientific, USA) at 450nm wavelength with 
595nm measurements collected for background correction. All samples were 
measured in duplicate, and measurements accepted if the coefficient of variation was 
less than 10%. Five-parameter logistic regression was used to fit the standard curves 
and calculate the sample concentrations using Sigmaplot, version 11.  
Chapter 2: Discovery and validation of diagnostic serum biomarkers for pancreatic cancer 
                     56 
2.2.5 Statistical Analysis 
For the purposes of selecting the best fit model of protein biomarker combinations, 
stepwise logistic regression was performed using JMP’s minimum corrected Akaike 
Information Criterion (AIC) procedure.  
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2.3 Results 
2.3.1 Identification of candidate biomarkers differentially regulated prior 
to diagnosis (UKCTOCS cohort) 
The characteristics of the pre-diagnosis patient cohort are shown in Table 2.2.  
 
Before statistical analysis of the Myriad Rules-Based Medicine data, any analytes 
where 20% or more of the samples were deemed to be below the LLOQ were 
excluded. The study was designed to include the measurement of effects from several 
proteins combined in a logistic regression model, so excluding a large proportion of 
samples due to one protein’s missing data when combining with other proteins would 
be problematic. In the UKCTOCS sample set, 17 protein analytes out of 101 were 
excluded in this manner. 
Table 2.2. Patient characteristics of UKCTOCS pre-diagnostic and matched control 
serum samples 
 0-6 months 6-12 months 
12-24 
months 
24-36 
months 
36-48 
months 
 PDAC Ctrl PDAC Ctrl PDAC Ctrl PDAC Ctrl PDAC Ctrl 
n 9 11 6 9 5 9 5 8 5 8 
Median 
age 
(range) 
69 
(53-
73) 
68 
(58-
74) 
58 
(51-
69) 
67 
(50-
77) 
63 
(52-
68) 
60 
(52-
73) 
65 
(57-
68) 
64 
(52-
70) 
60 
(56-
66) 
63 
(51-
72) 
Abbreviations: PDAC – pancreatic ductal adenocarcinoma, ctrl – healthy control 
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2.3.2 CA19-9 and CA125 serum concentration increases up to one year 
prior to diagnosis 
Mann Whitney U tests were performed using JMP version 11 (SAS Institute Inc., 
USA), comparing each PDAC time group set with its respective healthy control sera. 
This methodology does not assume that measurements follow a Gaussian 
distribution, meaning it could be applied to all proteins in the analysis. 
Of the proteins analysed, CA125 and CA19-9 concentration displayed the clearest 
relationship with time to diagnosis.  Despite modest sample sizes, both proteins were 
significantly upregulated in PDAC sera in the 0-6 month and 6-12 month groups 
(Figure 2-1).  
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2.3.3 Serum carcinoembryonic antigen and alpha fetoprotein increase in 
some PDAC patients prior to clinical diagnosis 
A clear pattern of protein concentration altering as time to diagnosis decreased was 
not observed among the other markers, when PDAC samples were compared with 
controls within the same time group. However, when all healthy control samples 
were treated as one group a statistically significant association between 
carcinoembryonic antigen (CEA) and alpha fetoprotein (AFP) concentration with 
time to diagnosis was revealed (Figure 2-2). CEA concentration was significantly 
upregulated in the 0-6 month cancer case group, with a corresponding trend observed 
in the 6-12 month group (Figure 2-2A). Significant or trending increases of AFP 
concentration were also observed in all time groups prior to the diagnosis of PDAC 
(Figure 2-2B).  
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Figure 2-1. Concentration of serum CA19-9 and CA125 is significantly 
upregulated up to one year prior to the diagnosis of PDAC. A) CA19-9 and B) 
CA125 were quantified in the sera of PDAC patients prior to clinical diagnosis using 
a Luminex platform.  Age- and centre-matched healthy control samples were also 
analysed for comparison. Error bars display median and interquartile range, p values 
calculated by Mann Whitney U. 
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Figure 2-2. Concentration of serum CEA and AFP is significantly upregulated 
up prior to the diagnosis of PDAC. A) CEA and B) AFP were quantified in the sera 
of PDAC patients prior to clinical diagnosis samples using a Luminex platform.  
Age- and centre-matched healthy control samples were also analysed for comparison. 
Error bars display median and interquartile range, p values calculated by Mann 
Whitney U. 
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2.3.4 Discovery of disease-specific biomarkers for pancreatic cancer 
The characteristics of the diagnosed patients (University of Liverpool collection) are 
shown in Table 2.3. As with the statistical analysis of the Myriad Rules-based 
Medicine data generated using UKCTOCS samples, analytes where greater than 20% 
of the sample measurements fell below the LLOQ were excluded from further 
analysis. Consequently, 20 out of 101 protein analytes were not included. 
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Table 2.3. Patient characteristics of diagnosed PDAC serum samples and controls 
with related disorders 
 
PDAC 
non-obs 
PDAC-obs BBO CP HC 
n  20 15 10 15 15 
Median 
age 
(range) 
 
64.5 
(39-78) 
67 
(39-78) 
65.5 
(24-80) 
48 
(36-78) 
35 
(23-65) 
Sex F/M 9/11 8/7 3/7 9/6 5/10 
Tumour 
stage 
T1 
T2 
T3 
I 
U 
- 
- 
10 
10 
- 
- 
- 
9 
5 
1 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
Resection 
margin 
R0 
R1 
I 
U 
1 
7 
10 
2 
4 
5 
5 
1 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
Abbreviations: PDAC – pancreatic ductal adenocarcinoma, BBO – benign biliary 
obstruction, CP – chronic pancreatitis, HC – healthy control, obs – obstruction, I – 
inoperable, U - unknown 
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2.3.5 No single protein is deregulated solely in pancreatic cancer patients 
Mann Whitney U tests were performed comparing sera from patients with PDAC 
with each benign control group. Of 81 proteins analysed, 71 had at least one 
significant difference between classification groups, though with so many 
comparisons a large number of these were likely due to chance.  
No significantly differentially-expressed proteins were specific for PDAC patients 
compared with all of the control groups. However, several promising markers were 
identified that individually were significantly upregulated in PDAC sera compared 
with healthy controls, obstructive jaundice or chronic pancreatitis patients (Figure 
2-3). 
Of all the cancer-control comparisons, as expected the most commonly observed 
differences were between the healthy controls and the PDAC serum samples, with 43 
(53%) of 81 analysed proteins showing significantly different expression in non-
jaundiced PDAC patients compared with healthy controls. In comparison, proteins 
that could discriminate PDAC patients from those with CP or patients with benign 
obstructive jaundice were much less prevalent. Comparisons of non-obstructed 
PDAC cases against CP revealed 11 proteins (14%) with significantly different 
expression, while a similar comparison between jaundiced PDAC cases and benign 
biliary obstruction revealed 10 (12%). 
CA19-9 and CA125 were again revealed as promising markers of PDAC, 
significantly upregulated compared with both chronic pancreatitis patients and 
healthy controls (Figure 2-3A, B). The hexameric glycoprotein tenascin C (TNC) 
was also upregulated in PDAC cases compared to CP, irrespective of obstructed 
jaundice status (Figure 2-3C). Of the many proteins differentially expressed in the 
disease groups compared with the healthy controls, the glycoprotein urokinase-type 
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plasminogen activator receptor (uPAR) demonstrated a particularly consistent 
upregulation across all disease groups (Figure 2-3D). Finally, phosphoserine 
aminotransferase (PSAT) and interleukin-6 receptor subunit β (IL-6Rβ, also known 
as gp130) were both significantly upregulated in benign obstructed jaundice cases 
compared with obstructed PDAC cases (Figure 2-3E, F). 
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Figure 2-3. Several serum biomarkers are required for discriminating PDAC 
from related disorders. Univariate analysis was performed on 81 proteins quantified 
by Luminex assay in the sera of healthy controls and patients with PDAC, chronic 
pancreatitis and benign obstructive jaundice. Examples are shown of proteins 
showing aberrant expression in PDAC cases compared with benign control groups. 
Error bars display median and interquartile range, p values calculated by Mann 
Whitney U. 
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2.3.6 Logistic regression analysis identifies potential biomarkers of 
PDAC  
All 81 proteins were entered into a stepwise logistic regression, performed using 
JMP’s minimum corrected Akaike Information Criterion (AIC) procedure to select 
the best fit model of protein biomarker combinations, generating models to classify 
two patient sample groups: PDAC versus CP and benign obstructed jaundice versus 
obstructed PDAC. 
For PDAC versus CP the procedure yielded five proteins to fit the model: CA19-9, 
TNC, receptor tyrosine-protein kinase erbB-3 (ErbB3), hepatocyte growth factor 
(HGF) and placenta growth factor (PlGF). The ROC curve from this combination 
yielded an AUC of 0.99, indicating a very high degree of accuracy. 
For benign obstructed jaundice vs obstructed PDAC three proteins were selected: IL-
6Rβ, uPAR and urokinase-type plasminogen activator (uPA). The ROC curve for 
this combination yielded a similarly high AUC of 0.97. 
While the ROC analysis of these models would indicate accurate classification of the 
patient samples, it is highly likely that they contain too many independent variables 
for the sample size of this study, and as a result the models are overfit126. A common 
rule applied to logistic regression analyses when selecting sample size is to ensure 
there are at least 10 events per predictor variable126,127. Subsequent work has 
suggested this may be too conservative, with a range of 5-9 events per parameter 
suggested to be acceptable though caution should be taken when interpreting 
results126,128. Either way, with the performed analyses based on a smallest group 
sample size of 15 and 10 patients respectively, it would be overoptimistic to consider 
a model with greater than two proteins to be accurate. 
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The proteins selected for each model were examined to see which were contributing 
the greatest effect. From the PDAC versus CP model only TNC, CA19-9 and ErbB3 
showed significant differential expression in PDAC sera when tested by Mann 
Whitney U, suggesting these were the markers classifying the bulk of the samples. In 
the case of ErbB3, significance was not retained when PDAC samples were 
classified by jaundice-status (p=0.28, CP vs. obstructed PDAC). ROC analysis of 
TNC and CA19-9 demonstrated encouraging accuracy in classifying samples, with 
an improved AUC when both markers were used in combination (Figure 2-4A). 
From the benign obstructed jaundice vs obstructed PDAC model both IL-6Rβ and 
uPA were significantly upregulated in benign obstructed jaundice cases compared to 
PDAC. ROC analysis indicated both markers performed better than CA19-9 alone, 
with IL-6Rβ having the superior AUC overall and uPA proving more sensitive at the 
cost of specificity (Figure 2-4B). 
With the aim of confirming the diagnostic utility of these biomarkers for PDAC, 
three proteins were selected for validation in independent sample sets: IL-6Rβ, TNC 
and PSAT. IL-6Rβ and TNC were selected based on performances in the relevant 
logistic regression analyses, while PSAT was selected based on its ability to discern 
some PDAC patients from both CP and benign obstructive jaundice patients in the 
discovery cohort. Work by other members of the group examining the most 
promising biomarker from the analysis, CA19-9, in serum was already ongoing 
before this work was undertaken. 
Chapter 2: Discovery and validation of diagnostic serum biomarkers for pancreatic cancer 
                     68 
  
0 
20 
40 
60 
80 
100 
0 20 40 60 80 100 
100-Specificity 
S
e
n
s
it
iv
it
y
 
CA19-9 (0.647) 
IL-6Rβ (0.840) 
uPA (0.773) 
B 
Figure 2-4 ROC curve analysis of promising markers’ diagnostic performance. 
Serum samples from A) chronic pancreatitis (n=15) vs. PDAC (n=35) and B) 
benign obstructive jaundice (n=10) vs. obstructed PDAC (n=15) cases were 
classified by protein expression to assess diagnostic accuracy. Area under the curve 
(AUC) is displayed in brackets. CA19-9 and TNC combination determined using a 
logistic regression model.  
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Validation of discovery markers 
2.3.7 Independent assay confirmation of IL-6Rβ, TNC and PSAT 
In order to test the validity of the initial findings of the Myriad Rules-based Medicine 
multiplex analysis, ELISA assays were undertaken individually for IL-6Rβ, TNC and 
PSAT on the same UoL serum samples as were sent for assay to Myriad RBM. Mann 
Whitney U analysis confirmed the original observations for TNC and IL-6Rβ from 
the multiplex analysis, but the results were not reproducible for PSAT (Figure 2-5). 
TNC was significantly upregulated in PDAC cases compared with CP patients, and 
showed a strong positive correlation with the multiplex results (Figure 2-5A). 
Similarly, IL-6Rβ concentration measured by ELISA also demonstrated good 
correlation with the multiplex data, and the upregulation in benign obstructed 
jaundice cases compared with obstructed PDAC was again observed (Figure 2-5B). 
In contrast, PSAT measured by ELISA showed no correlation with the original data 
and consequently no difference was observed between PDAC patients and either CP 
or benign obstructive jaundice cases (Figure 2-5C).  
An attempt was made at semi-quantitative analysis for PSAT using densitometric 
immunoblotting with a separate monoclonal antibody, probing serum samples at the 
high and low ends of the concentration spectrum established by the multiplex 
measurements, but no correlation was observed (Figure 2-6). It is possible that the 
antibody used for the multiplex analysis binds a particular component of the PSAT 
protein that is informative in this context, but as neither the ELISA nor the 
immunoblotting could reproduce the original results no further validation of PSAT 
was undertaken. 
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As the commercial ELISA kits suitably reproduced the results for IL6-Rβ and TNC, 
the analysis was subsequently extended to measure the proteins in an independent 
cohort of human serum samples.  
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Figure 2-5. Independent assay confirmation of biomarkers of interest. Concentrations 
of A) tenascin C, B) IL-6Rβ and C) PSAT in the discovery UoL serum set were determined 
by ELISA. Measurements were compared to the original Luminex data to assess 
reproducibility. Error bars display median and interquartile range, p values calculated by 
Mann Whitney U. 
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Figure 2-6. PSAT detected by immunoblotting in UoL serum samples. 
Pairs of serum samples were selected from each disease group. Samples 
with the highest and lowest PSAT concentration were chosen as measured 
by Myriad RBM to test for agreement.  
Abbreviations: BBO – benign biliary obstruction, CP – chronic pancreatitis, 
HC – healthy control, PDAC – pancreatic ductal adenocarcinoma, Obs - 
obstructed  
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2.3.8 Measurement of IL-6Rβ and TNC in an independent cohort of 
serum samples 
ELISA analysis for IL-6Rβ and TNC was repeated in a separate cohort of serum 
samples also collected by the University of Liverpool (Table 2.4). All conditions and 
protocols were consistent with those performed with the discovery sample set. 
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Unfortunately, the significant upregulation of IL-6Rβ in benign obstructed jaundice 
compared with obstructed PDAC cases observed in the discovery cohort was not 
observed in the validation set (Figure 2-7A). While IL-6Rβ concentration was still 
relatively high in the benign obstructive jaundice cases, a high enough proportion of 
patients in the obstructed PDAC group had similar concentrations, rendering IL-6Rβ 
an unsuitable marker for benign obstructed jaundice distinct from obstruction in 
PDAC. 
More promisingly, Mann Whitney U analysis of TNC in the validation cohort 
revealed a repeat of the pattern observed in the discovery cohort, with significant 
upregulation in PDAC cases compared to CP (Figure 2-7B). Thanks to work from 
other members of the group: Drs Claire Jenkinson, Victoria Shaw, Sarah Tonack and 
Mehdi Jalali, CA19-9 concentrations measured by ELISA were available for 34 of 
Table 2.4. Patient characteristics of diagnosed PDAC serum samples and controls 
with related disorders 
 
PDAC 
non-obs 
PDAC-
obs 
BBO CP HC 
n  35 52 29 50 36 
Median age 
(range) 
 
70 
(51-83) 
65 
(45-85) 
70 
(23-86) 
53.5 
(23-78) 
39 
(22-77) 
Sex F/M 20/15 28/24 13/16 17/33 28/8 
Abbreviations: PDAC – pancreatic ductal adenocarcinoma, BBO – benign biliary 
obstruction, CP – chronic pancreatitis, HC – healthy control, obs – obstruction 
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the 65 PDAC and 19 of the 35 CP samples analysed in this cohort. ROC analysis of 
these cases revealed TNC had greater accuracy than CA19-9 in distinguishing PDAC 
from CP patients, with a combination of the two markers providing the best AUC 
(Figure 2-8). The reproducibility of this finding in an independent cohort of serum 
samples suggests TNC may be a suitable biomarker in distinguishing patients with 
PDAC from those with CP, and is a candidate for entry into a panel of biomarkers 
that together would be specific and sufficiently sensitive for diagnosis of PDAC. 
 
 
 
Chapter 2: Discovery and validation of diagnostic serum biomarkers for pancreatic cancer 
                     76 
 
Figure 2-7. Serum IL-6Rβ and tenascin C in an independent cohort of serum 
samples. Concentrations of A) IL-6Rβ and B) tenascin C in an independent UoL 
serum set were determined by ELISA. Error bars display median and interquartile 
range, p values calculated by Mann Whitney U. 
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Figure 2-8. ROC curve analysis of CA19-9 against TNC in the validation cohort. 
Serum samples from patients with chronic pancreatitis (n=19) and PDAC (n=34) were 
classified by CA 19-9 and TNC concentration to assess diagnostic accuracy in the 
independent UoL serum cohort. Area under the curve (AUC) is displayed in brackets. 
CA19-9 and TNC combination determined using a logistic regression model. 
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2.4 Discussion 
This work had a number of phases. The initial phase involved subjecting serum 
samples from both pre-diagnosis and already diagnosed subjects to analysis for the 
levels of 101 cancer-associated analytes of the Myriad Rules-Based Medicine 
Human Oncology MAP. In the second phase, validation of potentially useful 
candidates (University of Liverpool, cohort only) was undertaken in the same 
samples as used in the original Myriad analysis. Analytes surviving this analysis 
were taken to a third phase of validation in independent samples from the University 
of Liverpool.  
In the pre-diagnostic cohort, CA125 and CA19-9, stood out as having the clearest 
relationship with time to diagnosis. Indeed, these promising findings confirmed 
results from work our collaborators were undertaking, and they have since extended 
the analysis to include other samples from the UKCTOCS collection, demonstrating 
that both markers show sensitivity up to two years prior to diagnosis129.  
Two other proteins that emerged with potential to discriminate pancreatic cancer 
from controls were CEA and AFP. In the case of both CEA and AFP, increases in 
median PDAC serum concentration were modest. CEA concentration in healthy 
control samples had low variation (range: 0.39-2.84 ng/mL), suggesting setting a 
threshold for cancer detection may be possible. CEA serum concentration as an 
identifier of colorectal cancer has been extensively studied and is reported to be 
highly specific, supporting this conclusion94. However, as a marker it has poor 
sensitivity and has been deemed unsuitable for mass screening.  
AFP had larger variability in the healthy control samples and the apparent increase in 
median serum concentration as time to diagnosis approached zero was skewed by 
two patients with serial sample measurements, who had consistently high levels in 
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the four years prior to diagnosis. This raises the possibility that AFP may be able to 
identify certain patients with PDAC at earlier time points than current diagnostic 
methods can provide, and is a potential candidate for further investigation in 
independent serum samples. Unfortunately, one of the great limitations of the study, 
especially with respect to UKCTOCS samples was very low number of samples sent 
for analysis. Moreover, I did not validate the markers identified using independent 
samples from this set. 
The University of Liverpool cohort offered the opportunity to examine for biomarker 
specificity. While no single marker showed up regulation or down regulation unique 
to the pancreatic cancer group, other interesting observations emerged, such as the 
identification of tenascin C as potential marker that can distinguish chronic 
pancreatitis from pancreatic cancer. The performance of this marker, withstood 
validation in an assay independent of that used by Myriad Rules-based Medicine. 
Having established a reliable method of testing this marker, it was important to 
repeat the measurements on an independent cohort of patient samples. Biomarkers 
measured in patients may fail to replicate initial findings in separate cohorts due to 
variability in ages, sex and race unaccounted for in the relatively small number of 
samples collected from such complex backgrounds130. Encouragingly, the levels of 
tenascin C remained significantly lower in chronic pancreatitis patients than in any 
other group in an independent validation set.   
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3.1 Introduction 
 
As described in Chapter 2, a commercial Luminex-based platform implemented by 
Myriad RBM with subsequent validation using ELISA analysis led to the 
identification of tenascin C as a potential biomarker for distinguishing PDAC 
patients from patients with chronic pancreatitis. Here I sought to determine whether 
this observation corresponded with TNC expression in the tissue microenvironment 
of pancreatic tissue from PDAC and CP patients. Staining for TNC protein and 
mRNA transcripts in whole tissue expression was performed to seek insight into the 
origin of secreted TNC, supplemented with data from primary cultured cancer-
associated fibroblasts. Finally, TNC expression on tissue microarrays constructed 
from CP and PDAC specimens was assessed to directly compare circulatory TNC 
with localised pancreatic expression. 
3.2 Materials and methods 
 
3.2.1 Immunohistochemical staining for TNC on PDAC and CP tissue 
IHC was performed for TNC using the same monoclonal antibody, described in 
section 0, that was used to coat the 96-well plate of the ELISA from the serum 
analysis (1:200, clone 4C8MS, cat. no. NB110-68136, Novus Biologicals, UK). 
Staining was performed on whole sections from PDAC and CP tissue specimens.  
Paraffin embedded blocks were cut into 4µm sections and mounted on histology 
slides (cat. no. 1014356190, Thermo Scientific, UK). After drying overnight at 40ºC, 
the sections were deparaffinised and antigen retrieval performed through boiling at 
95ºC in pH 9 antigen retrieval buffer (cat. no. K8004, Dako, UK) using a PT Link 
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(cat. no. PT10126, Dako, UK). Tris buffered saline (TBS, 2.4g Tris base, 8.8g NaCl 
in 1L dH2O, pH7.6) was prepared and used to make a 0.1% TBS Tween 20 solution 
(TBST). Sections were washed with TBST, leaving for three 1-minute incubations, 
before drying carefully with tissue and coating with peroxidase blocking reagent 
(Dako, UK) then leaving to incubate at room temperature for 10 minutes. Sections 
were washed again with TBST and dried, before covering with tenascin C antibody 
diluted 1:200 in antibody diluent (cat. no. S0809, Dako, UK) and leaving to incubate 
for 1 hour at room temperature. After a further wash and dry, labelled polymer anti-
mouse secondary antibody was added (Dako, UK) and incubated for another hour at 
room temperature. Another wash followed, before the addition of DAB+ chromogen 
(Dako, UK) for ten minutes at room temperature to visualise bound antibody. After a 
final wash with TBST, the sections were left to rest in distilled water before placing 
the slides in Gill III haematoxylin (cat. no. 3801540BBE, Leica Microsystems, UK) 
to counterstain for 30 seconds. Slides were subsequently washed for 5 seconds in 
dH2O, before rinsing in 0.25% hydrochloric acid for 5 seconds then placing in 2% 
ammonium hydroxide for a further 5 seconds. Slides were then placed in 90% 
ethanol for 1 minute, followed by 100% ethanol for a further 2 minutes, replacing the 
ethanol after the first minute. Finally, the slides were placed in xylene for two 1 
minute incubations in preparation for mounting in DPX (cat. no. 06522, Sigma-
Aldrich, UK).    
All sections were qualitatively reviewed by specialist histopathologist, Professor 
Fiona Campbell. 
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3.2.2 Haematoxylin and eosin staining 
Whole sections matched to those stained for TNC by IHC were deparaffinised in 
xylene and rehydrated by incubation for 2x30 seconds in serially decreasing 
ethanol/dH2O solutions from 100% to 95% to 70%, before rinsing in tap water. 
Slides were then incubated in haematoxylin for 10 minutes, rinsed in running tap 
water and agitated in 0.25% HCl/dH2O for 5 seconds. A further rinsing in tap water 
followed, before a 30 second agitated incubation in Scott’s tap water (1g potassium 
hydrogen carbonate, 10g magnesium sulphate in 500mL dH2O). After another rinse, 
slides were agitated in 100% ethanol for 30 seconds then placed in eosin Y (cat. no. 
3801600E, Leica Microsystems, UK) to incubate for 2 minutes. The slides were then 
agitated in 100% ethanol for 1 minute, followed by two 30 second washes in fresh 
ethanol and three 30 second agitations in fresh xylene before mounting in DPX. 
3.2.3 In situ hybridisation for TNC mRNA in PDAC and CP tissue 
specimens 
In situ hybridisation (ISH) was performed on serial tissue sections matched to those 
stained for TNC by IHC, using a commercial assay platform with probes specific for 
TNC (RNAscope® Reagent Kit, Advanced Cell Diagnostics, USA), visualised by 
DAB staining (cat. no. 310033, Advanced Cell Diagnostics, USA). The assay was 
performed according to manufacturer’s instructions. In brief, sections were 
deparaffinised in xylene and ethanol before permeabilisation and hybridisation of 
probes targeted to TNC RNA. A series of amplification steps followed through 
further hybridisation before a final addition of HRP-conjugated labelled probe was 
visualised by DAB chromogen reaction131. The amplification step enables 
visualisation of up to a single RNA molecule, with the number and size of punctate 
dots indicating the extent of RNA expression in each cell. Each run was 
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accompanied with sections probed for peptidylprolyl isomerase B (PPIB) as a 
positive control and dihydrodipicolinate reductase (dapB), a bacterial enzyme, as a 
negative control. 
3.2.4 Quantitative real-time PCR for TNC 
Quantitative real-time PCR (qPCR) was performed for TNC mRNA. cDNA was 
obtained from human fibroblasts cultured from different primary pancreas specimens 
with pathologies such as PDAC and CP, kindly provided by Dr Lawrence Barrera-
Briceno who also assisted with the qPCR experiments. All reactions were performed 
in a LightCycler® 480 (Roche Diagnostics Ltd., UK). The primer sequences used for 
TNC (Invitrogen™, Thermo Scientific, UK) are detailed in Table 3.1. Three 
housekeeping genes were also tested: GAPDH, β-actin and RPLP0, (proprietary 
sequences, Primer Design Ltd., UK). Real-time PCR reactions were carried out in a 
96-well plate in total volumes of 10µL per well, consisting of 10ng of cDNA for 
TNC and the housekeeping gene GAPDH plus 5µL LightCycler® 480 SYBR Green 
I Master mix (cat. no. 04887352001, Roche Diagnostics Ltd., UK). 500nM of 
forward and reverse primers for TNC and GAPDH were added. Sample reactions 
were run beginning with a 5 minute pre-incubation step at 95ºC, followed by 45 
cycles of denaturing for 10 seconds at 95ºC, 10 seconds at 60ºC for annealing and 10 
seconds at 72 ºC  for extension. Reactions were carried out in triplicate for each 
sample. Relative quantification was performed using the comparative CT method, 
using a Student’s t test to compare the two groups. CT values for all three 
housekeeping genes were consistent between CP and PDAC samples, so GAPDH 
was selected as the reference gene. 
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Table 3.1. Primers used for RT-PCR for TNC 
 
Sequence 
(5’-3’) 
TNC 
Forward 
Reverse 
ACCGCTACCGCCTCAATTAC 
GTTGTCAACTTCCGGTTCGG 
Abbreviations: TNC – tenascin C 
 
3.2.5 Immunohistochemical staining for TNC on tissue microarrays of 
PDAC and CP patients 
To compare the differences in TNC expression in PDAC and CP tissue on a larger 
scale, three TMAs were stained. Two of these consisted of FFPE tissue specimens 
from PDAC samples, with three cores sampled per patient, and were constructed by 
Dr Katharine Hand and Mrs Elizabeth Garner as part of a separate project. The third 
consisted of cores collected from fibrotic regions of CP tissue specimens as 
determined by a specialist histopathologist (Professor Fiona Campbell). This TMA 
was designed and constructed with the assistance of Mr Neal Rimmer, with four 
cores sampled per patient. 
After staining, cores were scored independently alongside Professor Campbell, 
noting whether the fibrotic stroma demonstrated positive staining for TNC. Where 
there were disagreements, a consensus was reached. Patients with less than two 
suitable cores for scoring were excluded from the analysis. 
3.2.6 Statistical analysis 
All statistical analyses were performed with JMP (Version 11, SAS Institute Inc., 
USA). Differences in serum biomarker concentration were tested between groups 
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using Mann Whitney U tests. Clinicopathological variable associations with data 
obtained from the TMAs were compared using Mann Whitney U, Pearson’s chi-
squared and Fisher’s exact tests as appropriate. Kaplan-Meier curves with log-rank 
tests were used to test the difference in overall survival between groups, where 
appropriate. 
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3.3 Results 
3.3.1 TNC is expressed in the tumour and stromal compartment of the 
PDAC microenvironment  
 
FFPE whole sections from PDAC and CP specimens were stained for TNC to assess 
expression within the diseased pancreas microenvironment. Heterogeneous staining 
was observed across and within PDAC patient sections, with strong staining 
occasionally observed within the tumour and stromal compartments. By contrast 
strong staining of the fibrotic components of CP was rarer, and was rather localised 
to periductal regions (Figure 3-1, left column). Strong staining of benign and 
malignant ductal epithelia was occasionally observed in CP and PDAC patients 
respectively, but there were also regions of strong staining in the desmoplastic 
stroma where the neighbouring epithelia remained negative. 
As high levels of circulatory TNC in PDAC patients may be related to high 
intratumoral protein expression, in situ hybridisation (ISH) for TNC was performed 
on tissue sections matched to those for which IHC was undertaken, in order to 
identify the cellular origin of TNC in PDAC and CP patient tissue. Areas of protein 
expression confined to ductal epithelia had low mRNA expression, with no 
expression observed in the surrounding stroma (Figure 3-1, top row). Surprisingly, in 
areas of strong stromal protein expression without corresponding tumour expression, 
mRNA expression was often limited to isolated tumour cells, (Figure 3-1, second 
row from top), though this pattern varied across the tumour. In some areas only 
scattered cells with a fibroblastic phenotype appeared to express TNC mRNA, with 
no adjacent tumour expression (Figure 3-1, second row from bottom).  
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Figure 3-1. Tenascin C expression in PDAC and chronic pancreatitis. 
Immunohistochemistry and in situ hybridisation were performed for TNC in whole 
tissue sections from patients with PDAC and chronic pancreatitis. Arrowheads 
indicate the presence of strong mRNA expression in ductal cells. TNC expression 
varied within and between PDAC patient tissue specimens, observed in both stromal 
and ductal epithelial compartments of the tissue microenvironment. Stromal and 
ductal expression was also apparent in chronic pancreatitis. Scale bars = 100µm. 
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In the CP cases, areas with positive benign ductal epithelia and surrounding 
desmoplasia had mRNA expression confined to the ductal compartment in a similar 
manner to that seen in some areas of PDAC. Though other CP cases were also 
probed for mRNA, the tissue sections were not suitably intact after processing to 
enable a comparison with the IHC-stained sections. This was due to the presence of 
calcified stones in the specimens, a common feature of CP, preventing clean cutting 
with a microtome, hampering the mounting of tissue sections to the slide and 
rendering them vulnerable to pieces breaking away. Consequently, further 
histological investigations comparing PDAC with CP were limited to TMAs so that 
areas of calcification could be deliberately avoided. 
 
3.3.2 Tenascin C is significantly overexpressed in PDAC stroma 
compared to CP 
TMAs containing tissue from patients with PDAC and CP were stained for TNC and 
scored based on expression in the stromal compartment of each disease type (Table 
3.2). Of all 35 CP patients, only 5 (14%) were positive for TNC, compared with 32 
(60%) of 53PDAC cases (p<0.0001, Pearson’s chi-square). This observation 
compared favourably with real-time PCR data quantifying TNC mRNA in primary 
human fibroblasts isolated from resected CP and PDAC tissue. Relative 
quantification indicated an increase in TNC expression in PDAC-associated 
fibroblasts compared to CP-associated (mean fold expression change=1.83), though 
this did not reach statistical significance (p=0.18, Figure 3-2). 
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Table 3.2 Patient characteristics of TMAs stained for TNC. 
 
PDAC TMA 
#1 
PDAC TMA 
#2 
CP TMA 
n  17 36 35 
Age 
Median 
(range) 
67 
(54-81) 
68 
(52-84) 
51 
(21-77) 
Sex F/M 11/6 16/20 19/16 
Abbreviations: PDAC – pancreatic ductal adenocarcinoma, CP – chronic pancreatitis 
 
 
Figure 3-2. TNC mRNA expression in human fibroblasts isolated from resected 
pancreatic tissue from patients with CP and PDAC. Quantitative real-time PCR 
was performed for TNC, normalised to GAPDH. Error bars display the mean and 
standard error. 
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Twenty-nine patients across all three TMAs had matching serum samples analysed 
for TNC concentration. Interestingly, no direct relationship was observed between 
serum TNC concentration and positive stromal expression (p=0.96, Figure 3-3), 
which remained the case if patients were also split according to disease (p=0.83 and 
0.48 for CP and PDAC, respectively).  
 
 
 
 
 
Figure 3-3. Concentration of serum TNC in PDAC and CP patients classified by 
protein expression in the tissue microenvironment. Error bars display median and 
interquartile range. 
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3.4 Discussion 
 
The identification of tenascin C as a potential biomarker for PDAC compared to 
patients with chronic pancreatitis warranted further investigation, as circulating 
markers that can distinguish pancreatic cancer from chronic pancreatitis are sorely 
needed92 . 
This is because pancreatitis is a risk factor for PDAC, and the two conditions can 
present concurrently. We therefore sought to determine whether the tissue levels of 
TNC in pancreatic cancer and in pancreatic patients might explain the differences in 
the circulating levels of this protein. Of note, immunohistochemistry was performed 
for TNC using the same primary antibody used in the serum ELISA study, described 
in section 0. This was to ensure that the form of the TNC protein being measured 
matched that detected in the serum, as TNC has several splice variants thought to 
relate to certain clinical outcomes  and may be associated with specific pathological 
contexts132. 
We observed variability in TNC expression suggesting a dynamic regulation of TNC 
within the PDAC microenvironment, where it can be produced and either secreted or 
retained by ductal epithelia and occasionally cells with a fibroblast phenotype. 
Significantly, TNC expression was more frequently observed in patients with PDAC 
compared to patients with CP. This suggests that there may be a relationship between 
expression in pancreas tissue and the concentration of TNC in the circulation. Given 
the mRNA evidence that TNC can be produced in PDAC tumour cells and secreted 
into the surrounding stroma, it is possible that intratumoral TNC entering the 
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circulation could account for the higher serum levels observed in PDAC patients 
compared to CP. However, our analysis of serum TNC levels and pancreatic tissue 
levels failed to show any direct correlation. This suggests that while increased levels 
of circulatory and pancreas-localised TNC are observed in more PDAC patients than 
CP, the use of TMAs may not be suitable as a means of accurately quantifying tissue 
expression to relate to the systemic levels observed in the circulation. It is possible 
that the circulating TNC derives from tissues/organs other than the pancreas. TNC 
expression is thought to be low or absent in healthy adult tissues, with transient 
upregulation reported at sites of injury, with functional links to inflammation and 
tissue repair132,133.  As TNC upregulation has been described at sites of skin, lung, 
cardiac and vascular injury there are a number of potential sites of origin for 
circulatory TNC. The fact that elevated serum TNC has been reported in patients 
with acute myocardial infarction also supports this132,134. With multiple splice 
variants of TNC thought to be functionally distinct, it is possible that the variants 
detected by the antibody used in this study may be more specific for PDAC 
compared to CP, despite both diseases involving inflammation of the pancreas. 
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4.1 Introduction 
 
Prior discovery work conducted by my research colleagues identified 
thrombospondin-1 (TSP-1) as a promising biomarker for early diagnosis in the 
UKCTOCS cohort. Drs Claire Jenkinson and Victoria Elliott quantified the levels of 
proteins in pooled serum samples by subjecting those samples to protein digestion 
using trypsin and tagging the resultant peptides with 8-plex isobaric tags for relative 
and absolute quantification (iTRAQ). Each pool contained serum from different 
disease categories and control groups, from 1) the UoL collection: PDAC (obstructed 
and non-obstructed), healthy control, benign biliary obstruction and chronic 
pancreatitis samples; and 2) from the UKCTOCS collection: 0-6 month and 6-12 
month pre-diagnosis PDAC samples with matched controls. Unique tags labelled 
each group to enable relative quantification using mass spectrometry. This revealed 
thrombospondin-1 (TSP-1) as a promising candidate for early diagnosis, with 
significantly reduced fold-changes in the 0-6 month and 6-12 month PDAC cases 
compared to healthy controls and in the UoL sample healthy controls compared to 
PDAC135.  
Validation of TSP-1 levels in independent samples from the UoL and UKCTOCS 
cohorts was undertaken by Drs Claire Jenkinson and Victoria Elliott. Quantification 
was performed using multiple reaction monitoring (MRM), a mass spectrometry-
based method used for absolute quantification in serum. Two target peptides were 
selected, unique to TSP-1, with three optimum transitions chosen and measured in 
trypsinised peptide digests derived from single serum samples. These measurements 
were compared with standard curves prepared from known concentrations of the 
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selected peptides, diluted in a peptide digest from human serum. MultiQuantTM 
software (Version 2.1) was used to analyse the peak area for each peptide transition 
and calculated concentrations of TSP-1 per sample using software-generated 
standard curves. Conventionally, studies examining circulatory proteins use ELISAs 
to determine concentration, including those investigating TSP-1 in the context of 
other cancers136,137. As MRM is a relatively new technique, here I used the more 
conventional ELISA and immunoblotting approaches to assess TSP-1 levels, and in 
doing so, to validate the MRM method established here. Moreover, I also assessed 
TSP-1 levels in sera derived from a genetically engineered mouse model for PDAC, 
and performed IHC for the assessment of TSP-1 levels in pancreatic cancer tissue. 
4.2 Materials and methods 
 
4.2.1 Serum ELISA for TSP-1 
Pre-diagnosis PDAC serum samples from the UKCTOCS collection were selected 
from 27 patients up to 2 years prior to diagnosis, along with 27 matched controls for 
the quantification of TSP-1 by ELISA (cat. no. DTSP10, R&D Systems, UK). The 
assay was performed according to manufacturer’s instructions, with all samples run 
in duplicate and accepted for further analysis if the coefficient of variation was less 
than 10%. Average readings for the duplicates were calculated. 
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4.2.2 TSP-1 knockdown 
Human foreskin fibroblast cells (HFF, American Type Culture Collection, UK) were 
cultured at 37ºC in a 5% CO2 atmosphere, in Dulbecco’s Modified Eagle’s Medium 
(DMEM, Life technologies, UK) supplemented with 10% foetal bovine serum (FBS, 
Life technologies, UK) and 1% L-glutamine (Sigma-Aldrich, UK). Cells were 
passaged every 2-3 days when confluence reached ~80%. 
Prior to short interfering RNA (siRNA) treatment, 70,000 cells per well were seeded 
in a 6-well tissue culture plate (Appleton Wood, UK). After 24 hours, the cells were 
ready for transfection at a confluence of ~40%. SiRNA for TSP-1 (Cat no. D-0197-
01-0002, Thermo Scientific, UK) was mixed in 200µL Opti-MEM I (Life 
technologies, UK), and incubated at room temperature for five minutes alongside a 
separate solution of 200µL Opti-MEM containing 4µL Lipofectamine 2000 (Life 
technologies, UK). The two solutions were mixed in equal volumes and left to 
incubate at room temperature for a further 30 minutes. 400µL of this solution was 
added dropwise to each well to make a final concentration of 30nM. Each siRNA 
treated well was run alongside three control groups: DMEM only, RISC-free siRNA 
(Cat. no.  D-001220-01-05, Thermo Scientific, UK) and a non-targeting siRNA pool 
(cat. no. D-001810-10-20, Thermo Scientific, UK). Following treatment, cells were 
incubated for 72 hours at 37ºC before protein extraction. 
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4.2.3 Protein extraction  
RIPA buffer (150mM sodium chloride, 1% Triton X-100, 0.5% sodium 
deoxycholate, 0.1%SDS, 50mM Tris pH 8.0) was prepared and mixed with a 
protease inhibitor cocktail (cat. no. 11 836 170 001, Roche Diagnostics GmbH, 
Germany) to complete the cell lysis buffer. Cells were washed with cold phosphate 
buffered saline (PBS, Sigma-Aldrich, UK) and 120µL lysis buffer added before cell 
removal from the plate using a cell scraper. The cell suspensions were mixed and 
incubated on ice for 5 minutes, repeating this process twice further. The lysate was 
then centrifuged at 17000g for 10 minutes at 4ºC. The supernatant was subsequently 
collected and stored at -80ºC for future use. 
4.2.4 Protein quantification and western blot analysis 
In preparation for western blot analysis, the total protein concentration of the cell 
samples were determined with a bicinchoninic acid (BCA) assay (cat. no. 23225, 
Thermo Scientific, UK) according to  manufacturer’s instructions. A 5x concentrated 
stock of reducing sample buffer (1g SDS, 5mL glycerol, 300mM Tris, 5mg 
bromophenol blue in 10mL dH2O) was prepared and mixed with a 1M solution of 
dithiothreitol (DTT) in a ratio of 3:2 to produce a loading buffer. Sample volumes 
containing 20µg total protein were each mixed with 3µL of loading buffer and 
enough 1x reducing sample buffer to equalise the total volume between samples. 
Samples were then incubated at 90ºC for 15 minutes, cooled to room temperature and 
centrifuged at 17000g for 10 seconds. Samples were loaded into precast acrylamide 
gels (cat. no. 4569034, Bio-Rad Laboratories, UK) in running buffer (3.03g Tris 
base, 14.4g glycine, 1g SDS in 1L dH2O) before running the gel at 270V for 30 
minutes.  
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Semi-dry transfer of the proteins from the gel to a PVDF membrane (cat. no. 
1704156, Bio-Rad Laboratories, UK) was performed using a Trans-Blot Turbo 
system (Bio-Rad Laboratories, UK) using the Mixed MW protocol (1.3A, up to 25V, 
7 minutes). TBS (2.4g Tris base, 8.8g NaCl in 1L water, pH7.6) was mixed with 
Tween 20 (TBST, Sigma-Aldrich, UK), with 1mL Tween per 1L TBS. A blocking 
solution of 5% milk/TBST was prepared and used to block the PVDF membranes for 
2 hours at room temperature. This was followed by overnight incubation at 4ºC with 
anti-TSP-1 monoclonal antibody diluted 1:400 in 5% milk/TBST. 
Membranes were then washed with TBST every 10 minutes for one hour prior to a 
further incubation with anti-mouse HRP-bound immunoglobulins (cat. no. P0447, 
Dako, UK) diluted 1:3000 in 5% milk/TBST for 1 hour at room temperature. A 
further hour of 10 minute-interval washes followed, before a 3 minute incubation 
with Western Lightning Plus (cat. no. NEL105001EA, Perkin Elmer, UK) 
chemiluminescent substrate and visualisation of antibody-bound protein using x-ray 
film (cat. no. 12715325, Sigma-Aldrich, UK). To test for equal loading, membranes 
were washed in TBST and probed with a monoclonal anti-β-actin antibody (cat. no. 
A5441, Sigma-Aldrich, UK) diluted 1:10000 in 5% milk/PBST for 30 minutes, 
before washing and probing with secondary antibody as before. 
4.2.5 Semi-quantification of TSP-1 in human and murine serum by 
western blotting 
Serum samples from the UKCTOCS and UoL cohorts were also analysed by western 
blotting using the protocol described in Chapter 4 Section 4.2.4, with the exception 
that a fixed volume (4µL) of sample per well was used instead of a fixed quantity of 
protein. This was to ensure the density of the bands observed were proportional to 
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the amount of TSP-1 protein per unit volume, to make readings comparable with 
concentrations derived by quantitative methods. 
With the assistance of Dr Claire Jenkinson, samples were run on 15-well gels (cat. 
no. 4569036, Bio-Rad Laboratories, UK) alongside pooled healthy control serum, 
loaded in 2µL, 4µL and 6µL volumes to act as standards for each gel. If the 
standards demonstrated a good linear fit after measurement (R>0.95) the gel was 
accepted and samples were normalised to the 4µL standard reading to allow 
comparisons across gels. All samples were run and analysed so that readings were 
available at least in triplicate. Densitometry was performed using ImageJ (version 
1.45) to give a quantitative reading for each sample (Figure 4-1).    
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-1. Overview of densitometric measurement of band intensity using 
imageJ. Shown is an example of a western blot for TSP-1, containing serum 
samples from the UKCTOCS collection. Each detectable band is measured as a 
peak, from which the background can be subtracted before the area under the peak is 
quantified. 
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Table 4.1. Clinical characteristics of KPC mouse serum cohort. 
 
Normal 
pancreas 
Low grade 
PanIN 
PanIN III PDAC 
n  9 6 1 3 
Median 
age/days 
(range) 
 
66 
(42-159) 
53 
(42-63) 
172 
(-) 
157 
(154-161) 
Sex F/M 9/0 6/0 1/0 3/0 
Abbreviations: PanIN – pancreatic intraepithelial neoplasm, PDAC – pancreatic 
ductal adenocarcinoma 
4.2.6 Serum from LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (KPC) 
and LSL-Trp53R172H/+;Pdx-1-Cre (PC) mice.  
Serum samples collected at the University of Cambridge from LSL-KrasG12D/+;LSL-
Trp53R172H/+;Pdx-1-Cre (KPC) mice at different stages of PDAC, age-matched with 
LSL-Trp53R172H/+;Pdx-1-Cre (PC) control mice were the kind gift of Professor David 
Tuveson. All mice were treated in accordance with institutional and European 
guidelines (Legislative Order No. 116.92). Blood was collected via cardiac bleed 
under isofluorane gaseous anaesthesia from 10 KPC and 9 PC controls (Table 4.1). 
Samples were allowed to clot for 2 hours at room temperature before centrifugation 
at 1000g for 20 minutes. Serum was then collected and snap frozen in liquid nitrogen 
prior to storage at -80ºC. Histological assessment confirmed the presence of PDAC 
and PanIN.  
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4.2.7 Confirmation of TSP-1 monoclonal antibody specificity by 
immunocytochemistry 
The same monoclonal antibody used for western blotting (clone A6.1, cat. no. MA5-
13398, Thermo Scientific, UK) was selected for immunohistochemical (IHC) 
staining to allow the direct comparison between serum and tissue TSP-1 expression. 
To confirm the specificity of the antibody when used for tissue staining, 
immunocytochemistry was performed on paraffin embedded HFF cells treated with 
siRNA for TSP-1 and control off-target siRNA as previously described. After 72 
hours of treatment, cells were washed in PBS and harvested using a cell scraper 
before centrifugation at 200g for 10 minutes. The supernatant was discarded and the 
cell pellets stored at -80ºC ready for fixation. Formalin fixation and paraffin 
embedding (FFPE) of the pellets followed, kindly performed by Mrs Elizabeth 
Garner. 
Embedded cell blocks were cut into 4µm sections and mounted on histology slides 
(cat. no. 1014356190, Thermo Scientific, UK). After drying overnight at 40ºC, the 
sections were deparaffinised and antigen retrieval performed through boiling at 95ºC 
in pH 9 antigen retrieval buffer (cat. no. K8004, Dako, UK) using a PT Link (cat. no. 
PT10126, Dako, UK). Tris buffered saline (TBS, 2.4g Tris base, 8.8g NaCl in 1L 
dH2O, pH7.6) was prepared and used to make a 0.1% TBS Tween 20 solution 
(TBST). Sections were washed with TBST, leaving for three 1-minute incubations, 
before drying carefully with tissue and coating with peroxidase blocking reagent 
(Dako, UK) then leaving to incubate at room temperature for 10 minutes. Sections 
were washed again with TBST and dried, before covering with TSP-1 monoclonal 
antibody diluted 1:100 in antibody diluent (cat. no. S0809, Dako, UK) and leaving to 
incubate for 1 hour at room temperature. After a further wash and dry, labelled 
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polymer anti-mouse secondary antibody was added (Dako, UK) and incubated for 
another hour at room temperature. Another wash followed, before the addition of 
DAB+ chromogen (Dako, UK) for ten minutes at room temperature to visualise 
bound antibody. After a final wash with TBST, the sections were left to rest in 
distilled water before placing the slides in Gill III haematoxylin (cat. no. 
3801540BBE, Leica Microsystems, UK) to counterstain for 30 seconds. Slides were 
subsequently washed for 5 seconds in dH2O, before rinsing in 0.25% hydrochloric 
acid for 5 seconds then placing in 2% ammonium hydroxide for a further 5 seconds. 
Slides were then placed in 90% ethanol for 1 minute, followed by 100% ethanol for a 
further 2 minutes, replacing the ethanol after the first minute. Finally, the slides were 
placed in xylene for two 1 minute incubations in preparation for mounting in DPX 
(cat. no. 06522, Sigma-Aldrich, UK).    
4.2.8 Immunohistochemical staining for TSP-1 on a tissue microarray of 
PDAC patients 
A tissue microarray (TMA), constructed by Mrs Elizabeth Garner, consisting of 
tissue from 49 FFPE PDAC specimens was stained for TSP-1 using the same 
conditions as for the ICC. Two cores of tissue were mapped to the TMA per patient, 
with each core scored by a specialist histopathologist (Professor Fiona Campbell). 
Cores were scored as positive or negative based on observed staining in the tumour 
or stromal compartment. 
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4.2.9 Statistical analysis 
All statistical analyses were performed with JMP (Version 11, SAS Institute Inc., 
USA). Differences in serum biomarker concentration were tested between groups 
using Mann Whitney U tests. Clinicopathological variable associations with data 
obtained from the TMAs were compared using Mann Whitney U, Pearson’s chi-
squared and Fisher’s exact tests as appropriate. Log-rank tests were used to test the 
difference in overall survival between groups, where appropriate. 
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4.3 Results 
 
4.3.1 Comparison of MRM and ELISA for analysis of TSP-1 in pre-
diagnostic PDAC serum  
ELISAs were performed on UKCTOCS pre-diagnosis PDAC cases and controls to 
compare with data obtained by MRM (Table 4.2). Comparing each time group with 
their respective controls, the median concentration of TSP-1 as measured by ELISA 
was consistently lower in each time group (Figure 4-2A), although this did not reach 
statistical significance. In contrast, the same samples analysed by MRM revealed 
significantly reduced concentration in pre-diagnosis PDAC patients in the 0-6 month 
category, with a trend observed in the pre-diagnosis cases up to 2 years prior to 
diagnosis (Figure 4-2B). This pattern was consistent with that observed in the 
original iTRAQ discovery work. 
 
 
 
Table 4.2. UKCTOCS patient characteristics for samples measured by ELISA 
for TSP-1 
 
0-6 
months 
6-12 
months 
12-24 
months 
 PDAC Ctrl PDAC Ctrl PDAC Ctrl 
n 8 8 8 8 11 11 
Median age 
(range)  
61.5 
(53-73) 
67.5 
(56-73) 
65 
(53-74) 
64 
(52-76) 
62 
(52-71) 
60 
(51-73) 
Abbreviations: PDAC – pancreatic ductal adenocarcinoma, Ctrl – healthy control 
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The pattern observed in the TSP-1 ELISA data suggested immuno-based approaches 
were comparable to MRM, but details on which monoclonal antibody was used to 
coat the plate was proprietary and thus unavailable to me. A different candidate 
antibody was selected for testing with the aim of confirming the MRM results with 
an independent assay, mainly western blotting and eventually analysing TSP-1 
expression in the PDAC tumour microenvironment.  
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Figure 4-2. Serum TSP-1 levels in pre-diagnostic PDAC samples. TSP-1 
concentrations were measured by A) ELISA and B) MRM in pre-diagnostic PDAC 
samples and matched healthy controls. Error bars display median and interquartile 
range, p values calculated by Mann Whitney U. 
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4.3.2 Monoclonal antibody for TSP-1 confirmed as specific for TSP-1 in 
serum and fibroblasts 
Expression of TSP-1 was detectable by western blotting in untreated HFF cells, with 
a strong downregulation of protein observed after treatment with siRNA for TSP-1 
(Figure 4-3). Probing for TSP-1 in sera alongside HFF cell lysate revealed a band at 
the same molecular weight, confirming antibody specificity in both clinical sample 
sets (Figure 4-3). Importantly, a range of band intensities were observed across 
samples, suggesting that densitometric analysis of the bands would be a suitable 
semi-quantitative method for analysis of TSP-1 levels. 
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Figure 4-3. Variable concentration of TSP-1 in diagnostic and pre-diagnostic 
PDAC serum confirmed by western blotting. Serum from the UoL and 
UKCTOCS collections were blotted on a membrane and probed with a monoclonal 
antibody for TSP-1. The specificity of the antibody was confirmed by siRNA 
inhibition of TSP-1 expression in human foreskin fibroblasts. Probing for β-actin 
was performed as a measure of loading in the cell samples. 
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Table 4.3. Patient characteristics of UKCTOCS serum samples measured for 
TSP- by western blotting. 
 0-6 months 6-12 months 12-24 months 
 PDAC Ctrl PDAC Ctrl PDAC Ctrl 
n 30 30 17 17 17 17 
Median 
age 
(range) 
66 
(51-74) 
64 
(51-76) 
68 
(51-74) 
67 
(50-76) 
62 
(52-71) 
60 
(51-73) 
Abbreviations: PDAC – pancreatic ductal adenocarcinoma, Ctrl – healthy control 
 
4.3.3 Semi-quantitative analysis of TSP-1 serum concentration in UoL 
and UKCTOCS samples 
 
The analysis was expanded to include all UKCTOCS and UoL serum samples 
measured by MRM (Table 4.3, Table 4.4). Median TSP-1 levels were lower in 
cancer compared to control in all groups, and this reached statistical significance in 
the 6-12 months pre-diagnostic group (Figure 4-4A). In contrast, the UoL cohort 
measurements demonstrated significantly reduced levels of TSP-1 in the PDAC 
cases compared to healthy controls, irrespective of jaundice-status (Figure 4-4B). 
Correlative analysis also suggested the antibody performance differed between the 
two cohorts. A weak positive association with the MRM data was observed in the 
UKCTOCS cohort (r=0.27, Figure 4-4C) where a stronger one was observed in the 
UoL samples (r=0.48, Figure 4-4D).  
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Table 4.4. Patient characteristics of UoL serum measured for TSP-1 by western 
blotting. 
 
PDAC 
non-obs 
PDAC-
obs 
BBO CP HC 
n  49 48 20 29 24 
Median age 
(range) 
 
67 
(39-82) 
65 
(39-85) 
65.5 
(24-80) 
52 
(36-77) 
34.5 
(23-71) 
Sex F/M 28/21 26/22 5/15 16/13 8/16 
Tumour 
stage 
T1 
T2 
T3 
I 
U 
1 
3 
31 
12 
2 
- 
2 
36 
8 
2 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
Resection 
margin 
R0 
R1 
I 
U 
10 
24 
12 
3 
10 
28 
8 
2 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
Abbreviations: PDAC – pancreatic ductal adenocarcinoma, BBO – benign biliary 
obstruction, CP – chronic pancreatitis, HC – healthy control, obs – obstruction, I – 
inoperable, U - unknown 
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Figure 4-4. Semi-quantitative analysis of TSP-1 in sera from the UoL and UKCTOCS 
cohorts. A) Pre-diagnostic and B) Clinical serum samples were separated and transferred onto 
PVDF membranes before probing for TSP-1 with a monoclonal antibody and quantified by 
densitometry. Data were then compared with their respective MRM measurements in the C) 
UKCTOCS and D) UoL cohorts. Error bars display median and interquartile range, p values in 
A) and B) calculated by Mann Whitney U. 
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4.3.4 Confirmation of low serum TSP-1 in a genetically engineered 
mouse model for PDAC 
KPC mouse-derived samples were immunoblotted and quantified by densitometry 
alongside age-matched PC control mice (Table 4.1). Low TSP-1 levels were 
observed in mice diagnosed with PDAC compared to high or low grade PanIN and 
control mice (Figure 4-5). 
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Figure 4-5. Semi-quantification of TSP-1 in KPC mouse sera with matched healthy 
controls. Western blotting for TSP-1 was performed on serum from KPC mice 
sacrificed at different stages of PDAC development, alongside age-matched healthy 
controls. An example blot is shown with the TSP-1 band indicated by the arrowhead. 
The dot plot is representative of one of three runs. The difference between PDAC and 
control sample measurements did not reach statistical significance across all three runs, 
so no p values are displayed here. Error bars display median and interquartile range. 
Abbreviations: HC – healthy control. 
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4.3.5 Clinicopathological analysis of TSP-1 expression in the PDAC 
tumour microenvironment 
Serum TSP-1 levels as measured by MRM showed promise as an early diagnostic 
marker for PDAC. Kaplan-Meier analysis conducted by Dr Claire Jenkinson also 
suggested a prognostic role for TSP-1; patients with lower levels of TSP-1 had 
poorer overall survival135. To investigate whether varying levels of serum TSP-1 
were reflected in the tumour, immunohistochemistry for TSP-1 in a tissue microarray 
(TMA) of PDAC specimens was performed. 
4.3.6 Confirmation of immunohistochemical specificity of clone A6.1 
TSP-1 antibody 
Under the same RNAi conditions used for the western blot analysis, a robust 
confirmation of successful TSP-1 downregulation was observed when measured by 
ICC (Figure 4-6). Consequently, these conditions were kept constant for further 
immunohistochemical work on human tissue specimens. 
 
 
 
 
 
 
Figure 4-6. Specificity assessment of monoclonal TSP-1 antibody for 
immunocytochemistry. HFF cells treated with off-target siRNA and siRNA 
for TSP-1 were embedded in paraffin and stained for TSP-1. Scale bar=60μm 
Off-target siRNA TSP-1 siRNA 
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4.3.7 TSP-1 tissue expression in PDAC cases is not associated with 
overall survival 
A TMA constructed from PDAC patient tissue specimens was stained for TSP-1. 
Heterogeneous staining of tumour and stromal staining was observed across patients, 
with TSP-1 expression observed in tumour cells and desmoplastic stroma in some 
patients, but no expression observed in others (Figure 4-7). In total, 32 (65%) of the 
49 patients were negative for TSP-1, with 17 (35%) having positive staining in either 
the stroma or tumour. Univariate analysis found no association between TSP-1 
expression and other clinicopathological parameters, including overall survival 
(Table 4.5, Figure 4-8).  
 
 
Negative PDAC Positive PDAC Positive stroma 
T
S
P
-1
 
Figure 4-7. Examples of TSP-1 staining by IHC in PDAC tissue.  Heterogeneous TSP-1 staining 
was observed in the tumour and stromal compartments of PDAC tissue. Scale bar=100µm. 
Chapter 4: Examination of thrombospondin-1, a promising diagnostic biomarker for pancreatic 
cancer, in serum and the tumour microenvironment 
                     116 
Table 4.5. Univariate analysis of PDAC patient TMA stained for TSP-1. 
 
Cases 
(n=49) 
TSP-1 
Positive 
TSP-1 
Negative 
P value 
Age 
Median 
(range) 
67 
(51-84) 
67 
(51-84) 
66.5 
(52-81) 
0.77 
Sex 
Male 
Female 
25 
24 
9 
8 
16 
16 
1.0 
Diabetic 
Yes 
No 
Unrecorded 
11 
30 
8 
5 
9 
3 
6 
21 
5 
0.46 
Resection 
margin 
R0 
R1 
Unrecorded 
10 
20 
19 
3 
4 
10 
7 
16 
9 
0.66 
Tumour 
stage 
T1 
T2 
T3 
T4 
Unrecorded 
0 
3 
43 
2 
1 
0 
2 
13 
1 
1 
0 
1 
30 
1 
0 
0.38 
Nodal 
involvement 
R0 
R1 
10 
39 
4 
13 
6 
26 
0.72 
Platelet 
count 
Median 
(range) 
303.5 
(31-809) 
296 
(208-456) 
312 
(31-809) 
0.70 
P values determined by Mann Whitney U, Pearson’s chi-squared and Fisher’s Exact tests as 
appropriate. 
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Figure 4-8.  Kaplan-Meier analysis for overall survival in PDAC patients, 
classified by TSP-1 tissue expression. A TMA of PDAC patient tissue was scored 
based on positive TSP-1 expression in tumour or desmoplastic stroma. TSP-1+ n=17, 
TSP-1- n=32. 
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4.4 Discussion 
 
The use of a targeted mass-spectrometry based approach addresses the weaknesses of 
immunoassays for quantifying proteins in serum, in that they require the targeting 
antibody to be highly specific and are prone to interference from endogenous human 
anti-reagent antibodies138,139. However, the discovery of a potential marker, TSP-1 
with lower circulating levels in PDAC patients than healthy subjects warranted 
independent validation in serum and investigation in primary tissue specimens using 
immunohistochemistry, requiring the identification of a suitable antibody. 
An ELISA assay was initially employed to determine TSP-1 levels in UKCTOCS 
samples using a non-mass spectrometry based approach. Although I consistently 
measured lower levels in cancer case groups than controls, this did not reach 
statistical significance. It was impossible to validate the specificity of the antibody 
used in the ELISA, as all information pertaining to this antibody was proprietary. 
Therefore, a western blotting approach was adopted, with HFF cells, which have 
previously been reported to express TSP-1, considered a suitable positive control cell 
line for testing the antibody140,141. Western analysis on UKCTOCS samples again 
showed lower levels in pre-diagnostic cases compared to controls, however only 
reaching significance in the 6-12 month time group. The correlation between 
Western and MRM was better in the UoL samples, suggesting that the sample 
processing differences between the two cohorts may have had an effect on antibody 
affinity for TSP-1. This, coupled with the fact that the antibody used has shown weak 
cross-reactivity with thrombospondin-2 when used for western blotting142, suggested 
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MRM was the most appropriate method for quantifying TSP-1 in the two human 
serum cohorts.  
The LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (KPC)  mouse model of PDAC has 
been well characterised and is thought to faithfully reproduce the human disease 
from the pre-neoplastic stage to the development of advanced and metastatic 
cancer143.   
I observed that the specificity of the TSP-1 antibody was poorer when used to probe 
the murine samples, possibly due to the murine origin of the monoclonal antibody 
requiring an anti-mouse secondary antibody for visualisation, with the potential for 
cross-reaction with other serum proteins (Figure 4-5). Analysis of serum from KPC 
mice indicated that circulating TSP-1 was decreased in mice with PDAC, but not 
with pre-malignant PanIN lesions. This supports the findings observed in the human 
samples, and raises the possibility that decreases in serum TSP-1 observed in the pre-
diagnostic cases are occurring in the context of fully developed PDAC. It also 
suggests that the use of genetically engineered mouse models for identifying early 
diagnostic markers may be a valid strategy. 
Perhaps in contrast to the analysis of TNC expression in pancreatic cancer tissue in 
chapter 3, the use of IHC to identify TSP-1 expression in the tumour 
microenvironment did not help explain the reduced levels of TSP-1 in the serum. At 
present we do not have a mechanism to explain these observations.  
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5.1 Introduction 
 
In chapters 3 and 4, I attempted to relate the circulatory levels of TSP-1 and TNC to 
their respective pancreatic tissue levels. In the case of TNC, the higher levels 
observed in the circulation of pancreatic cancer patients compared to patients with 
chronic pancreatitis correlated with high stromal tissue expression in cancer tissue 
compared to chronic pancreatitis tissue (p<0.0001, Chapter 3 Section 3.3.2). This 
suggested a link between TNC protein expression in the tumour or chronic 
pancreatitic microenvironment and the levels of the TNC protein in the circulation. 
However where data were available to compare TNC levels in matched pancreatic 
tissue and blood a correlation between tissue and circulating TNC levels could not be 
established (Chapter 3 Section 3.3.2). While there are a number of possible 
explanations for this, one explanation relates to the possible inadequacy use of tissue 
microarrays as a means of quantifying elements of the PDAC tumour 
microenvironment. We hypothesised that TMAs may provide too small an area of 
tissue to accurately quantify pancreatic stromal expression.  
PDAC has a complex stromal compartment consisting of extracellular matrix, 
immune cells, fibroblasts, endothelial cells and soluble proteins, thought to 
contribute to tumour cell survival, proliferation, immune evasion and resistance to 
therapy 33–35. Given the heterogeneity of the disease, it is not known whether the use 
of TMAs is appropriate for analysing all elements of the PDAC stroma. 
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To address this question, myself and two other research group members, Dr 
Katharine Hand and Mrs Frances Oldfield, undertook a study assessing the suitability 
of quantifying stromal components using TMAs in relation to clinical outcome. One 
of the PDAC TMAs analysed for TNC expression (Chapter 3 Section 3.2.5) was 
produced as part of this project, enabling me to compare this with other stromal 
components of the PDAC tumour microenvironment. 
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5.2 Materials and methods 
 
5.2.1 Tissue microarray construction 
 A TMA was constructed by Mrs Elizabeth Garner. Three cores per patient were 
sampled from FFPE tumour specimens from 47 patients with PDAC. The TMA was 
cut into 192 sections of 5µm thickness, dipped in paraffin wax and stored at -20ºC. 
5.2.2 Immunohistochemical staining of TMA sections 
Antibodies and histological stains were selected to characterise various components 
of the stroma. At least four sections, at different depths within the array, were stained 
for the detection of each marker. IHC was performed following the protocol detailed 
in Chapter 3 Section 3.2.1, with an extra deparaffinisation step at the beginning. 
Slides were equilibrated to room temperature then placed in xylene and incubated for 
30 minutes, or until the paraffin coating the slide was removed. Slides were then 
placed in 100% ethanol for 1 minute, before insertion into a PT Link (cat. no. 
PT10126, Dako, UK) for antigen retrieval. Subsequent steps were performed as 
described in Chapter 3 Section 3.2.1, using the antibody dilutions described in Table 
5.1. All TMAs were stained alongside whole PDAC sections known to express the 
proteins of interest, as well as with polyclonal anti-mouse immunoglobulin-HRP 
conjugates (cat. no. P0447, Dako, UK) to serve as negative controls. Stained TMAs 
were scanned with an Aperio ScanScope™ (Leica Microsystems, UK) and mapped 
for scoring using Definiens Tissue Studio (version 3, Definiens, Germany). 
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Table 5.1. Antibodies and histological stains used for stromal component visualisation 
Antibody/stain 
Stromal 
component 
stained 
Catalogue 
number 
Supplier 
Antibody 
dilution 
Stained 
by 
Scored 
by 
Anti-α-SMA 
Activated 
fibroblasts 
ab7817 Abcam, UK 1:50 
AE & 
FO 
AE & 
FO 
Anti-CD204 
M2 
Macrophages 
KT022 
Transgenic 
Inc., Japan 
1:200 KH 
AE & 
FO 
Anti-CD206 
M2 
Macrophages 
ab117644 Abcam, UK 1:200 KH 
AE & 
FO 
Anti-CD68 Macrophages M0876 
Dako UK Ltd., 
UK 
1:100 
AE & 
FO 
AE & 
FO 
Anti-CD8 
Cytotoxic T 
cells 
M7103 
Dako UK Ltd., 
UK 
1:1000 TG 
AE & 
FO 
Anti-
cytokeratin 
Epithelia 4545S 
Cell Signaling 
Technology, 
Inc., USA 
1:300 KH 
AE & 
FO 
Anti-
podoplanin 
Lymphatic 
vessels 
 
Fibroblasts 
M3619 
Dako UK Ltd., 
UK 
1:100 
AE & 
FO 
AE & 
FO 
Haematoxylin 
& Eosin 
All 
3801540B
BE 
 
3801600E 
Leica 
Microsystems, 
UK 
- KH - 
Masson’s 
trichrome 
Collagen HT15-1KT 
Sigma-Aldrich, 
UK 
- KH - 
Abbreviations: SMA – smooth muscle actin 
Initials: AE – Anthony Evans, FO – Frances Oldfield, KH – Katharine Hand, TG – Thompson Gana  
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5.2.3 Scoring of tissue microarrays 
All stains were optimised and scored in consultation with a specialist 
histopathologist, Professor Fiona Campbell. TMAs from four depths spanning the 
full TMA block were evaluated for the presence of tumour in all cores, to ensure that 
the stroma being scored in every core was associated with malignancy. 
Blinded independent scoring was performed alongside Mrs Frances Oldfield. On all 
TMAs, cores were only scored if at least half of the core contained intact tissue. 
TMAs stained for α-smooth muscle actin (αSMA) and cytokeratin were scored as a 
percentage of non-necrotic tissue in each core. Stained podoplanin was scored as a 
percentage of αSMA stained tissue in the next serial section, ensuring that 
podoplanin-stained TMAs were always within two sections (~10µm) of matched 
αSMA TMAs.  
Stained immune cells (CD8, CD204, CD206, CD68) were counted manually. As 
some cores had missing tissue as a result of the staining process, an adjustment factor 
was applied if necessary based on the percentage of tissue remaining, either 50%, 
75% or 100%. 
Where there was disagreement over cores scored by percentage, a consensus was 
reached. For counted markers, if count values were not within 20% of each other 
then both investigators performed a recount until this criterion was met. Once a 
consensus for all cores was reached, the average of the scores was taken as the final 
core value. The average of all cores per patient was then calculated as the value used 
for further analysis. On each TMA section, a patient was only included in the 
analysis if at least two cores were available for scoring, with the average of all cores 
used to calculate the final score per patient. To calculate the overall mean per patient 
across all TMA levels, at least five cores had to be present. 
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Activated stroma index (ASI) was determined using ImageJ (version 1.5) software, 
calculated as the proportion of collagen stained for αSMA for each core: ASI = 
αSMA area (µm2) ÷ collagen area (µm2)90. Using ImageJ’s colour deconvolution 
plugin144, αSMA and collagen staining were isolated from their respective cores by 
segregating three colours from the original images. Optimal colour settings were kept 
consistent across all analysed TMAs (Table 5.2). Deconvoluted images were 
converted to binary 8-bit greyscale images, using the ‘Triangle’ auto-threshold 
algorithm, and scaled to enable the measurement of each stained area in µm2. ASI 
was calculated from two serial TMAs stained for αSMA by IHC and collagen with 
Masson’s trichrome stain.  
 
 
 
Figure 5-1. Examples of αSMA and collagen staining isolated from background 
counterstain using ImageJ’s colour deconvolution plugin. Original core images 
are displayed in the top row, with isolated staining post-deconvolution shown 
underneath. Activated stroma index was calculated from the quantified area of 
αSMA staining as a proportion of collagen-stained area, both in µm2. 
αSMA Trichrome collagen 
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5.2.4 Luminex quantification of serum cytokines, chemokines and 
growth factors 
Data were available from a comprehensive analysis of sera from the University of 
Liverpool collection, performed by other members of the research group104, 
quantifying 27 cytokines, chemokines and growth factors. These data, kindly 
provided by Dr Victoria Shaw, were matched with the patients on the TMA to 
compare stromal scores with serum cytokine concentrations.  
Table 5.2. Settings applied for ImageJ colour deconvolution 
plugin. 
Colour settings  αSMA Collagen 
Colour 1 
R 
G 
B 
0.6027735 
0.644836 
0.46994755 
0.76523894 
0.5705916 
0.29805133 
Colour 2 
R 
G 
B 
0.34126425 
0.56168777 
0.753688 
0.5437807 
0.6563658 
0.52295935 
Colour 3 
R 
G 
B 
0.7212509 
0.5183564 
0.45946032 
0.34454608 
0.4935677 
0.79854804 
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5.2.5 Statistical analysis of TMA scored data 
Clinicopathological data for each patient was matched with stroma data after scoring 
was completed, both at a TMA section level and at the entire TMA level, using all 
available scoring data across all TMA depths. Associations of stromal component 
scores with other clinical parameters were calculated using Pearson’s chi-squared, 
Fisher’s exact and Mann Whitney U tests as appropriate. Kaplan-Meier analysis for 
overall survival was performed using log-rank tests to test for differences between 
groups, after splitting the patients by median stromal component expression. 
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5.3 Results 
5.3.1 Construction and staining of a TMA for the quantification of 
stromal components 
The characteristics of the 47 PDAC patients, whose samples were used to generate 
the TMA in this study are shown in Table 5.3. The TMA was sectioned completely, 
such that TMA sections from several depths of the TMA block could be 
histologically stained for each marker, as illustrated in (Figure 5-2). All antibodies 
(Table 5.1) were optimised for IHC and deemed suitably specific for their respective 
targets (Figure 5-3). 
Figure 5-2. Overview of stromal quantification study design. A TMA containing cores 
from 47 PDAC tissue specimens were cut into 192 sections to enable staining and analysis 
for multiple stromal components at different depths.  
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Table 5.3. Patient characteristics of PDAC 
samples on the stroma study TMA 
 Cases (n=47) 
Median age 
(range) 
 
68 
(44-84) 
Sex F/M 22/25 
Tumour stage 
T1 
T2 
T3 
1 
2 
44 
Resection margin 
R0 
R1 
R2 
9 
37 
1 
Lymph node 
involvement 
N0 
N1 
11 
36 
Median tumour 
size/mm 
(range) 
 
 
30 
(18-60) 
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Figure 5-3. Examples of stromal components stained on a TMA of PDAC tissue specimens. 
Arrowheads indicate examples of fibroblasts stained for podoplanin. Scale bars=100μm. 
  
CD68 CD206 CD204 
CD8 Trichrome Podoplanin 
Cytokeratin H&E αSMA 
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IHC for αSMA revealed strong staining of fibrous tissue consistent with its 
expression in activated fibroblasts, as well as smooth muscle where present. Staining 
for pan-cytokeratin was also consistent with expectations, demonstrating strong 
cytoplasmic expression in malignant and benign epithelia. Intermittent podoplanin 
expression was observed in fibroblast-like cells, though its intended use as a marker 
was originally for lymphatic vessels. This observation was consistent with previous 
reports linking podoplanin expression in cancer-associated fibroblasts with prognosis 
in other carcinomas145,146. Consequently, podoplanin-stained TMAs were scored as 
the percentage of αSMA-positive areas from matched serial TMAs, cut within two 
sections (~10µm), to investigate if this prognostic effect was also observed in PDAC. 
As expected, IHC for immune cells revealed scattered cytoplasmic staining of 
individual cells rather than areas of block staining. Cells stained for CD68, a marker 
of macrophages, and CD204 and CD206, both thought to be expressed in M2 
macrophages, were highly abundant and phenotypically characteristic of 
inflammatory cells147. CD8+ cytotoxic T cells were also stained in a specific manner, 
but were much lower in abundance. 
 
5.3.2 Quantification of stromal elements reveals variable expression at 
different depths of the TMA 
Consistent with our experience with other TMAs, for all stromal markers the number 
of scorable cores decreased at lower depths of the TMA block compared with upper 
depth levels. This resulted in reduced numbers of patients suitable for analysis at 
each level, as the TMA depth increased (Table 5.4).  
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Table 5.4. Details of TMA scored for PDAC stromal components at different 
depths. Slide number represents the position of the TMA section in relation to the 
TMA block, with Slide 1 representing the first section cut. 
Scored 
stromal 
feature 
Slide number 
Number of 
patients 
Scoring 
method 
Median score 
αSMA+ 
1 
30 
47 
76 
106 
Overall 
40 
34 
36 
29 
18 
41 
Percentage 
42.5 
51.7 
58.3 
47.9 
57.5 
52.6 
Cytokeratin+ 
6 
36 
48 
66 
77 
96 
107 
Overall 
41 
42 
24 
36 
31 
28 
25 
45 
Percentage 
25.0 
18.3 
30.0 
20.0 
18.8 
22.5 
20.0 
19.7 
Activated 
stroma index 
1 32 Percentage 65 
Podoplanin+ 
fibroblasts 
31 
49 
78 
108 
Overall 
32 
30 
29 
18 
37 
Percentage 
53.3 
55 
40.8 
27.5 
41.6 
CD68+ 
16 
51 
80 
110 
Overall 
44 
34 
31 
26 
39 
Count 
129.7 
140.6 
141.2 
120.5 
128.5 
CD204+ 
13 
43 
73 
103 
Overall 
38 
38 
28 
28 
39 
Count 
77.8 
95.2 
109.3 
111.3 
91.6 
CD206+ 
15 
45 
105 
Overall 
44 
37 
25 
40 
Count 
80.6 
87.3 
89.3 
92.3 
CD8+ 
10 
40 
70 
100 
Overall 
45 
41 
28 
29 
42 
Count 
26.2 
21.8 
25.7 
14.9 
25.8 
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The median percentage area of αSMA-stained tissue per patient core was 
consistently higher than cytokeratin+, suggesting the majority of tumours on the array 
had a pronounced desmoplastic component in comparison to areas of tumour. The 
median αSMA+ percentage for each TMA level varied, however, ranging from 42.5-
58.3% with an overall median of 52.6%, taking into account patient cores across all 
TMA levels. Similarly median cytokeratin+ percentages also fluctuated at different 
TMA levels, ranging from 18.3-30%. Despite a different scoring method, 
podoplanin+ staining scored as a percentage of αSMA+ stroma was also highly 
variable, ranging from 27.5-55%.  
All scoring and statistical analysis was performed independently by both myself and 
Mrs Frances Oldfield. The results of the complete analysis of αSMA, podoplanin, 
cytokeratin and ASI staining will be presented in her thesis, while in this thesis I will 
focus on the detailed analysis of the inflammatory components. 
Median counts of CD204+ and CD206+ cells were consistently lower than CD68+ 
cells, supporting the notion that they comprised a subset of CD68+ macrophages 
(Table 5.4). In comparison, CD8+ cytotoxic T cells were much lower in abundance 
than the macrophage-type cells, with an overall median of 25.8 cells per patient core. 
Comparisons of the overall mean number of CD68+, CD204+ and CD206+ cells per 
patient revealed a strong positive correlation between the three groups, further 
suggesting that the three groups are linked (Figure 5-4A-C). Interestingly, though 
both markers were selected to stain M2 macrophages, CD204+ and CD206+ cell 
correlation with each other was the weakest of the three, suggesting they may not be 
staining exactly the same macrophage subtype or that the antibodies used to strain 
them differed in specificity. 
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A weak positive relationship was also observed between CD8+ cells and CD68+ 
macrophages (Figure 5-4D) and CD206+ M2 macrophages (Figure 5-4F) but not 
CD204+ cells (Figure 5-4E). 
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Figure 5-4 Scatter plots of immune cells quantified using a TMA of PDAC samples. A-
C) Correlative comparison of CD68+, CD204+ and CD206+ macrophages stained on a TMA 
of PDAC tissue, sectioned for analysis at different depths of the tissue block. D-F) 
Comparisons of CD68+, CD204+ and CD206+ macrophages with CD8+ cytotoxic T cells. 
The mean number of cells per patient, measured across all TMA levels, is plotted.   
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5.3.3 Inflammatory cells do not correlate with serum cytokines and 
chemokines 
Overall mean CD68+, CD204+, CD206+ and CD8+ cell counts were correlated with 
matched serum concentrations of cytokines, chemokines and growth factors 
measured by Luminex assay. No significant relationships were identified, except for 
a weak positive association between CD8+ cell count and serum macrophage 
inflammatory protein-1α (MIP-1α, Table 5.5). 
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Table 5.5. Correlation of mean immune cell count with matched serum cytokine, 
chemokine and growth factor concentration. The mean number of cells per patient, 
scored on a TMA sectioned for analysis at different depths, was compared with 
matched serum concentrations of 25 cytokines. 
 Immune cell correlation (Spearman’s rho) 
 CD68+ CD204+ CD206+ CD8+ 
PDGF 0.1549 0.1273 -0.0067 -0.0675 
IL-1β -0.0865 -0.0292 -0.0199 -0.0428 
IL-1Ra -0.0548 -0.1503 -0.0054 0.1886 
IL-2 0.1565 0.0441 -0.0015 0.2581 
IL-4 -0.0596 -0.0505 -0.0629 0.0065 
IL-5 0.0005 0.0963 0.0242 -0.0675 
IL-6 -0.0315 0.0327 0.0994 0.1423 
IL-7 0.0224 0.0087 0.0499 -0.0613 
IL-8 -0.0177 -0.0107 -0.0079 -0.0491 
IL-9 0.0469 0.2541 0.0956 0.234 
IL-10 0.1341 0.1639 0.211 0.033 
IL-12 0.2346 0.1128 0.2299 0.2805 
IL-13 0.0654 0.152 0.0537 0.0607 
IL-17 0.0187 0.1508 -0.0824 0.1837 
Eotaxin -0.0718 -0.1366 0.0369 0.1109 
FGF basic -0.0961 0.0413 -0.086 0.1874 
G-CSF 0.0208 0.1318 -0.0048 0.1484 
IFN-γ -0.0645 -0.0007 -0.0513 -0.0591 
IP-10 0.0247 -0.0778 0.0198 0.2068 
MCP-1 0.0947 0.1366 0.0921 -0.1109 
MIP-1α 0.0151 0.1879 0.1219 0.3189* 
MIP-1β -0.1343 0.0434 -0.0349 -0.0006 
RANTES 0.1954 0.1811 0.1452 -0.1218 
TNF-α -0.0559 -0.0247 -0.0833 -0.052 
VEGF 0.0728 0.0059 0.1163 -0.166 
*Significant correlations 
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5.3.4 Tenascin C stromal expression is associated with increased 
activated stroma index and CD68+ macrophage abundance 
 
One of the PDAC TMA sections assessed for tenascin C expression, as described in 
Chapter 3 3.2.5, was used to investigate if TNC stromal expression related to the 
abundance of other stromal elements in PDAC. For the purposes of this analysis, 
TNC stromal expression status was categorised as present or absent and plotted 
against the overall mean values of inflammatory cell counts and examined for 
differences. Though no strong relationship was observed with either of the M2 
macrophage marker scores (Figure 5-5A, B), the number of CD68+ macrophages was 
increased in patients with positive TNC stromal expression (Figure 5-5C). 
Interestingly, though no difference was observed in αSMA abundance between 
patients positive or negative for TNC (p=1.0), activated stroma index values, a 
measure of αSMA-stained collagen, were higher in TNC+ patients (Figure 5-5D), 
suggesting that TNC expression is associated with the activation of fibroblasts in the 
desmoplastic stroma. 
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Figure 5-5. CD68+ cell numbers and activated stroma index are increased in PDAC patients 
with positive stromal TNC expression. PDAC patients were classified by TNC stromal 
expression on a TMA sectioned and stained for stromal analysis at different depths. A) CD204+, 
B) CD206+, and C) CD68+ mean cell counts per core and D) ASI values are plotted. P values 
derived by Mann Whitney U test, error bars display the median and interquartile range.  
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5.3.5 Survival analyses based on the inflammatory cell counts at 
different depths of the TMA yield variable conclusions 
 
Kaplan-Meier analysis for overall survival was performed for all TMA levels, 
categorising patients as ‘high’ (higher than the median count) and ‘low’ (lower the 
median count) for each marker. Preliminary analyses were performed at the 
individual TMA levels, treating each depth as a separate entity to reflect how an 
analysis would be performed were only one section of TMA analysed per marker. 
Four TMA sections were stained for each immune cell marker, though in the case of 
CD206 one section was insufficiently mounted in DPX and could not be scored. 
When analysed individually, high numbers of CD68+ and CD206+ cells were 
positively association with overall survival (OS) at the top level of the TMA (Figure 
5-6, top row), but not at any other level. The lack of association observed between 
OS and CD204+ cell count provided further evidence that population is not identical 
to that stained for CD206, or that there are differences in the specificity of the two 
antibodies used. 
CD8+ cells, though lower in abundance than the macrophages, demonstrated a 
similar pattern with overall survival, with a favourable prognosis associated with 
higher numbers at the top level of the TMA, but not at any other level (Figure 5-7). 
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Figure 5-6. Kaplan-Meier analysis for overall survival of PDAC patients on a TMA, sectioned for 
analysis at different depths. TMAs stained for the macrophage markers CD68, CD204 and CD206 were 
scored and patients grouped above and below the median number of cells per core. At least three TMA 
sections were stained per marker, with each section selected to be at least 150µm apart from each other. 
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Figure 5-7. Kaplan-Meier analysis for overall survival of PDAC patients on a 
TMA stained for CD8+ cells, sectioned for analysis at different depths. TMAs 
stained for CD8+ cytotoxic T cells were scored and patients grouped above and 
below the median number of cells per core. Four TMA sections were stained, with
each section selected to be at least 150µm apart from each other. 
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5.3.6 Kaplan-Meier analysis of inflammatory stromal elements across all 
TMA levels reveals no prognostic benefit to high abundances of CD8+, 
CD68+, CD204+ and CD206+ cells 
 
Given the inconsistent conclusions drawn from analysing each TMA at distinct 
depths, Kaplan-Meier analyses were repeated using the combined stromal scoring 
data from across all TMA levels. Accordingly, all available data per patient were 
used to calculate a final mean count per patient. Association with overall survival 
were not observed when patients were categorised as having high or low CD68+, 
CD204+ or CD8+ cell counts (Figure 5-8A, B, D). However, high numbers of 
CD206+ cells were still significantly associated with longer overall survival (Figure 
5-8C). 
The number of evaluable patients per section decreased when depth into the TMA 
block increased (Table 5.4). The possibility therefore arose that the greater patient 
numbers in the top level TMA stained for CD206 was a source of bias with respect to 
the overall mean values. The analysis was therefore repeated for CD206-stained 
TMAs, but included only 22 patients for whom scores were available on all three 
TMA levels. With this stipulation, the association of CD206+ cell abundance with 
OS was not observed on any level including when overall data per patient were 
applied (Figure 5-9).  
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Figure 5-8. Kaplan-Meier analysis for overall survival of PDAC patients on a TMA 
stained for cell markers at different depths. TMA sections stained by IHC for A) CD68+, 
B) CD204+, C) CD206+ and D) CD8+ cells were scored and averaged across all TMA depths. 
Patients were grouped above and below the median number of cells per core. At least three 
sections were stained per marker, with each section situated at least 150µm apart from each 
other. 
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Figure 5-9 Kaplan-Meier analysis for overall survival of PDAC patients on a TMA 
stained for CD206 at different depths. TMA sections stained for CD206 were scored and 
patients grouped above and below the median number of cells per core. Only patient samples 
present on all TMA levels were included. Plotted are survival curves for TMAs at the A) top, 
B) upper middle and C) bottom levels of the TMA, along with D) overall CD206+ cell counts 
per patient calculated from across all sections. 
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5.4 Discussion 
The lack of concordance between blood-borne TNC and stromal expression in the 
tumour microenvironment raised questions about the use of TMAs to quantify 
stromal characteristics in PDAC. TMAs are commonly used for histological staining 
assessment in cancer studies, providing numerous benefits over studying whole 
tissue sections when the analysis of large numbers of patients is desired148,149. The 
main benefit is in the time saved, as the retrieval of blocks for the cutting of sections 
followed by staining and assessment can take several months, and the process has to 
be repeated if the analysis of other markers is required. The assembly of a TMA is 
far more efficient, as once constructed a TMA can be sectioned potentially hundreds 
of times with each section providing a cohort of patients for analysis of distinct 
markers. By mapping numerous patient samples to the same section, this can account 
for staining performance affected by any batch variation. The portability of TMAs 
also eases collaboration between groups, providing opportunities for multi-centre 
studies and potentially more robust analyses of patient cohorts. 
These benefits are useful if an analysis of markers expressed in tumour cells is 
desired, as these can be identified on an array and scored with an appropriate 
method. Whether the use of TMAs is appropriate for studying stroma in PDAC, 
which in most cases forms the bulk of the tumour microenvironment, was one of the 
focuses of our group. 
In this chapter I have focused on the immune cell component quantified in this study. 
Positive correlations in the mean abundance of macrophages and M2 macrophages 
per TMA core were identified, suggesting that our method of quantifying these cells 
was robust and reproducible. Interestingly, CD204+ and CD206+ cells did not 
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correlate as strongly with each other as each did with CD68+ cells, despite both being 
putative markers for M2 macrophages147. A possible explanation could be 
differences in performances of the antibodies used to detect each marker, with 
differences in sensitivity and cross-reactivity affecting what cell types are quantified. 
Alternatively the M1/M2 macrophage paradigm is thought to represent extremes of 
macrophage classification, when it is more likely that the dynamic process of 
macrophage activation results in cells falling along a continuum61. If the expression 
of CD204 and CD206 varies for cells falling at different stages of the continuum, this 
could affect the final quantification of stained cells.  
More problematically, when investigating the relationship between immune cell 
prevalence and patient outcome, the conclusions drawn from TMA sections at 
different depths of the array were not consistent. This raises concerns that if only one 
section were cut from the array and stained for a particular stromal marker, as is 
typical in prognostic studies utilising TMAs, then the conclusions from the analysis 
may vary depending on where in the array that section was cut. Whether this 
possibility could be minimised by implementing certain measures in the study 
design, such as ensuring the number of cores per patient exceeds three, has not been 
addressed in this study. Guidelines suggest that the number of cores selected per 
patient be chosen based on the heterogeneity of the tumour being studied 150. Studies 
investigating the effect of core number in colorectal cancer, lung cancer and prostate 
cancer tissue conclude that 3-4 cores are optimal depending on the degree of 
heterogeneity of the tumour151–153. It is therefore possible that PDAC stroma 
heterogeneity requires at least four cores per patient to be sampled, especially given 
our observation that the number of total remaining cores decreases as the depth into 
the TMA increases.    
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Interestingly, the association of CD68+, CD206+ and CD8+ cell number with overall 
survival was only observed at the top level of TMAs stained for these markers. It is 
possible that the cores at this level share some characteristic to reveal this 
observation, though we have been unable to identify what this might be. Median 
expression of αSMA and cytokeratin, surrogate markers for desmoplastic stroma and 
tumour epithelia respectively, did not deviate highly at this level compared to others, 
suggesting that if there is an explanatory feature it is unlikely to be linked simply to 
bulk composition of the cores in terms of tumour and stroma. 
One of the TMA sections was stained for TNC expression, enabling comparisons 
with the other stromal elements to identify potential relationships. An association 
was found between positive TNC stromal expression and ASI, a measure of cancer-
associated fibroblast activity previously linked to patient outcome90. This provides a 
possible explanation for the heterogeneity of TNC expression in the PDAC tumour 
microenvironment. The fact that ASI is calculated by quantifying one stromal 
component as a proportion of another, suggests that scoring TMA cores relative to 
others can be informative, and may be useful for investigating crosstalk by elements 
of the stroma. This may also offer a method of bypassing the depth-dependent 
inconsistencies we have identified in this TMA, when comparing quantified stromal 
features with patient outcome. 
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6 DISCUSSION 
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6.1 Identification and validation of diagnostic biomarkers for 
pancreatic cancer 
 
The initial aims of this thesis were to identify and validate serum biomarkers for the 
diagnosis of PDAC, and investigate the expression of these markers in the tumour 
microenvironment. From there, with the assistance of Mrs Frances Oldfield, I 
investigated the suitability of using tissue microarrays for the quantification of 
stromal elements of PDAC. 
Myriad RBM-based quantification of 101 cancer-associated proteins in samples from 
UKCTOCS identified CA125 and CA19-9 as the most obvious markers associated 
with time to diagnosis, each significantly elevated up to a year prior to PDAC 
diagnosis compared to healthy controls. These findings corroborated observations in 
a study already underway by our collaborators, which included a larger set of 
samples from the UKCTOCS collection129. Both of these markers showed sensitivity 
up to two years prior to diagnosis129. 
CA19-9 was confirmed to be an informative marker in the UoL collection, with 
significantly increased concentrations in the PDAC cases compared to chronic 
pancreatitic and healthy controls. Though CA19-9 has been extensively studied, and 
deemed insufficiently specific as a screening tool for PDAC, I would suggest that 
CA19-9 should be used as part of a panel of biomarkers for this purpose94,95,99,100,108.  
CA19-9 is best recognised as a tool for disease management, used alongside imaging 
as an indicator of recurrence, progression or response to therapy94. The study by 
O’Brien et al. challenges this notion, suggesting that screening high risk populations 
for CA19-9 may lead to earlier diagnosis of PDAC in some patients129.  
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The complete analysis of the UoL cohort found no single marker uniquely 
distinguished PDAC cases from benign controls. However, several individual 
markers appeared to discriminate PDAC cases from specific control groups, in a 
manner that could be used in combination to increase the sensitivity and specificity 
for diagnosing PDAC from benign controls. Reliable assays were established to 
verify the Myriad RBM measurements for tenascin C and IL-6Rβ, markers that 
significantly discriminated PDAC from CP and benign obstructed jaundice cases 
respectively. These were tested in an independent cohort of patient samples from the 
UoL collection. Many biomarkers fail to replicate initial results due to the nature of 
relatively small sample sizes used for discovery work, especially when considering 
the variability and complexity of a potential screening population130. Reassuringly, 
significantly higher levels of TNC in PDAC patients compared to CP were also 
observed in the independent samples, demonstrating superior sensitivity and 
specificity to CA19-9 for the discrimination of these two groups. Logistic regression 
modelling to combine the two markers improved the diagnostic accuracy above 
either marker alone, further supporting the notion that a panel of biomarkers may be 
required to obtain suitable sensitivity and specificity for screening. 
Tenascin C is a large hexameric extracellular matrix glycoprotein that is highly 
expressed in the developing embryo but negligibly so in most healthy adult 
tissues132,154. Instead, transient expression is observed in sites of high cell turnover 
and tissue remodelling, and has been detected in areas of chronic inflammation 
including the stroma of several cancers such as breast, lung and ovarian tumours154. 
In PDAC, functional analyses of cell lines by Paron et al. suggest that TNC may play 
a complex role155. They identified a heterogeneous response to increasing doses of 
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exogenous TNC and growth on a TNC-rich matrix, inhibiting cell growth and 
migration in some cell lines but with the opposite occurring in others155.  
Identifying biomarkers that can distinguish pancreatic cancer from chronic 
pancreatitis has proven challenging, in part because pancreatitis is a risk factor for 
PDAC and the two conditions can present concurrently92,156. Consequently, we 
sought to explain the different TNC levels observed in the circulation of PDAC and 
CP patients by examining protein expression in the pancreatic tissue (Chapter 3). 
What emerged was a picture of dynamic regulation of TNC in the PDAC 
microenvironment, where TNC can be produced and secreted or retained in ductal 
epithelia of the tumour. Scattered stromal cells with a fibroblast-like phenotype were 
also occasionally observed to be sources of strong TNC expression in the 
desmoplastic stroma, a finding supported by in vitro analysis of cultured fibroblasts 
isolated from patient CP and PDAC tissue specimens. A relatively novel RNA in situ 
hybridisation technique identified tumour cells as the source of TNC protein 
expression in regions of positive stromal, even where no expression was observed in 
the epithelia131. This observation suggests that combining ISH and IHC to examine 
protein and mRNA expression in the context of a tissue microenvironment is a 
powerful technique, particularly in elucidating crosstalk between elements of the 
tumour and stroma. 
Studies from other groups have also reported diffuse TNC expression in the stroma 
surrounding malignant cells and PanIN lesions in a murine and human PDAC 
setting110,157,158. Esposito et al. reported moderate to strong TNC expression in eight 
(80%) out of ten CP tissue sections, a considerably higher percentage than the 14% 
of CP patients with TNC-positive stroma characterised in our study. Our use of a 
tissue microarray compared to whole section profiling could be a possible 
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explanation for this disagreement, as the area of tissue examined in this manner is 
much smaller than the area of tissue available in a whole section. However the use of 
a TMA was considered necessary, avoiding problems associated with cutting CP 
tissue blocks containing calcified stones. Another possible explanation is the 
difference in choice of antibody between studies. Tenascin C has several splice 
variants, and our choice of antibody (clone 4C8MS) was specific for those containing 
the FNIII B domain while that used in the Esposito et al. study (clone BC-24) is 
thought to recognise all isoforms of human tenascin132,154. The BC-24 antibody could 
therefore stain for an alternative splice variant of TNC, present in the stroma of many 
CP cases, where 4C8MS would not recognise the same. Our choice of antibody 
replicated the findings from the Myriad RBM serum analysis, and consequently was 
appropriate for meeting the primary aim of identifying diagnostic biomarkers. By 
using the 4C8MS antibody for both the serum and tissue analyses, we ruled out 
affinity for different TNC splice variants as the reason for differences in expression 
between the two compartments. 
 We observed that TNC-positive stroma was present in significantly more PDAC 
patients than CP, supporting the findings of the serum analysis. As the 4C8MS 
antibody was selected for IHC to match the ELISA used for the serum samples, this 
corroboration suggests it is important to keep antibodies consistent when comparing 
a protein’s tissue expression to circulatory levels. 
Despite the comparable overall pattern of increased TNC tissue expression and 
circulatory levels in PDAC compared to CP cases, no direct association was found 
between positive stromal expression and serum concentration. This could be 
explained by effects on circulating TNC by other tissues and organs, such as other 
sites of inflammation or fibrosis132,133. We also considered the possibility that TMAs 
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may not be a suitable method for accurately quantifying tissue expression, 
particularly for comparison with systemic measures of a marker. 
Mirus et al. also identified TNC as a diagnostic marker for PDAC in plasma from 
GEMMs and a pre-diagnostic human sample set110. Though they did not compare 
PDAC samples with plasma from CP patients, they did demonstrated that combining 
their panel of biomarkers with CA19-9 improved diagnostic accuracy, in agreement 
with our biomarker studies and others92,110,135.   
Discovery work on sera from the UKCTOCS and UoL collections by our group 
identified thrombospondin-1 as a promising candidate for early diagnosis of PDAC, 
using multiple reaction monitoring as a means of quantification. The use of a mass 
spectrometry-based method ensured unambiguous identification and quantification of 
the marker of interest, but as a relatively novel method I wanted to compare it with 
TSP-1 levels measured in both UKCTOCS and UoL serum collections using more 
conventional immunoassays. In doing so I also confirmed that the TSP-1 antibody 
(clone A6.1) was suitably specific for tissue analysis by IHC. 
Quantification of serum TSP-1 by ELISA and western blotting demonstrated a trend 
consistent with that observed when measured by MRM, though not as consistently 
statistically significant. However, the correlation between western blotting and MRM 
was stronger in the UoL samples compared to UKCTOCS, suggesting that the 
differences in sample processing had affected the antibody’s affinity for TSP-1. 
Moreover, a study by Annis et al. had reported weak cross-reactivity of our selected 
antibody (clone A6.1) with thrombospondin-2 when used for western blotting142. 
Together, this would suggest MRM is the most suitable method for quantifying TSP-
1 in our serum cohorts. Though optimising MRM assays for each protein of interest 
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can be time-consuming, the results of this study suggest it is an excellent technique if 
a suitably specific antibody cannot be acquired159. 
The observation that circulating TSP-1 levels were reduced in cases from the 
UKCTOCS cohort compared to controls suggested that this marker may change prior 
to the development of PDAC. We sought to independently address this question 
using sera from KPC mice collected at different stages of disease. This particular 
mouse model has been extensively studied and is thought to faithfully reproduce the 
development of PDAC from the formation of pre-neoplastic lesions to advanced and 
metastatic cancer143,160. Serum analysis for TSP-1 revealed low circulatory levels of 
TSP-1 in mice with PDAC but not in healthy mice nor in those bearing PanIN lesions 
alone. This raises the possibility that decreased TSP-1 levels observed in pre-
diagnostic sera occur in a background of already developed PDAC. It also suggests 
that genetically modified mouse models are an appropriate tool for identifying 
diagnostic biomarkers, as utilised by other studies92,110,120. 
At present we have not been able to identify a mechanism explaining the lower 
circulating levels of TSP-1. TSP-1 is a matricellular glycoprotein thought to be an 
attenuator of inflammation and inhibitor of angiogenesis, through interacting with 
endothelial cells in a CD36-dependent manner to induce apoptosis and inhibit cell-
cycle progression, as well as antagonising VEGF function in the extracellular 
matrix161,162. Consequently, it is thought to have anti-carcinogenic properties161. 
Reports investigating circulatory TSP-1 levels in other tumour contexts are mixed, 
with elevated plasma levels reported in breast cancer but decreased levels in serum 
from lung and prostate cancer patients163–165. Pan et al. measured TSP-1 in plasma 
from healthy subjects and patients with PDAC and chronic pancreatitis, using the 
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same ELISA kit used in Chapter 4, and observed slightly increased levels of TSP-1 
in cancer compared to the benign controls166. 
My colleagues extended the analysis of TSP-1 and demonstrated that combining with 
CA19-9 significantly improved diagnostic accuracy over either marker alone135. 
They also discovered a link between TSP-1 and PDAC-associated diabetes, noting 
significantly lower levels in the diabetic PDAC samples compared to non-diabetic 
cases and all other controls135. Though further work is needed to reveal the extent of 
this relationship, the identification of biomarkers specific for cancer-associated 
diabetes (type IIIC) compared to type II diabetes patients would be invaluable for use 
as a screening tool167. Future investigations into biomarkers for PDAC should 
consider diabetic subjects when selecting control groups to test against92. 
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6.2 Evaluation of tissue microarrays as a means of quantifying 
stromal elements of pancreatic cancer 
 
Both tenascin C and thrombospondin-1 circulating levels were compared with 
respective tissue expression to attempt to discern a relationship. Though the overall 
trends for TNC expression in tissue and serum between PDAC and CP patients were 
consistent, no direct correlation was found. We hypothesised that the use of TMAs 
for this analysis may be the cause, with too small an area of tissue examined to 
accurately quantify the pancreatic stromal expression. Given more time and sample 
availability, a comparison of circulatory levels with matched whole tissue sections 
may fully address this question. 
Elucidating the features and functions of stroma in PDAC is currently a highly active 
area of research, both in understanding the roles the various features play in tumour 
biology and as a target for therapy33,34. PDAC has a particularly pronounced stromal 
compartment, both at the site of origin and at distant metastases, consisting of 
extracellular matrix, soluble proteins, blood vessels, lymphatic vessels, immune cells 
and fibroblasts33–35,79. Tissue microarrays are commonly used for high powered 
cancer studies when histological assessment is required148,149. PDAC is no exception, 
where several studies have investigated the tumour and stromal compartments in 
tissue samples using this method89,168–170. The time saved using a TMA compared to 
analysing an equivalent number of patients separately, coupled with the overcoming 
of staining variation problems from batch effects, makes it a convenient method for 
quantifying and studying elements of the microenvironment. Given the results of the 
analysis of TNC and TSP-1 in Chapter 3 and Chapter 4 I, along with my colleagues, 
Chapter 6: Discussion 
                     161 
undertook a study investigating if the use of TMAs for quantifying stromal 
components was appropriate for PDAC. 
 To address this question, a TMA of PDAC patient samples was sectioned 
completely and stained for immune cells, desmoplasia and epithelia, to investigate 
stromal composition and consistency at different depths of the array. Counts for 
macrophages, stained for CD68, and M2 macrophages, stained for CD204 and 
CD206, strongly correlated with each other when mean patient values were matched, 
suggesting that our method of quantifying these cells was robust and reproducible.  
Macrophages are commonly classified as M1 or M2 macrophages, though most fall 
along a continuum, with M2-polarised macrophages thought to be more abundant in 
a tumour context61. Kurahara et al. reported greater numbers of M2 macrophages at 
the tumour invasive front associated with poorer overall survival in patients with 
PDAC, with a near-significant association also observed for CD68+ macrophages62. 
Our analysis of the relationship between macrophage abundance and prognosis 
yielded mixed results. At the top level, high CD68+ and CD206+ but not CD204+ cell 
counts were associated with a favourable prognosis, in contrast to the study by 
Kurahara et al. No association was observed at any of the other TMA depths, 
suggesting there was some as-yet-unidentified property of the cores at the top level 
TMA that gave this conclusion. It is possible that the random nature of what 
constitutes the cores on a TMA section, particularly once a TMA has been sectioned 
extensively, leads to a loss of information that can abrogate the usefulness of 
quantifying these cell types for prognostic analyses. Kurahara et al. limited areas of 
scoring to the invasive edge of the tumour before conducting their analysis, 
suggesting that such an approach may be required for the association of M2 
macrophages with survival to become apparent. 
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Ene-Obong et al. took a similar approach when noting an association between high 
numbers of CD8+ cytotoxic T cells and a more favourable prognosis post-
resection168. Here they quantified CD8+ cells in separate stromal areas, classified by 
proximity to tumour cells; they noted a significant survival benefit to high CD8+ 
abundance in the tumour-adjacent regions, but not when counting those from the rest 
of the stromal compartment. In a similar manner to the macrophage results, our 
analysis revealed a significant association between CD8+ cell count and prolonged 
survival but only at the top level of the TMA. In this context, it is possible that a 
greater number of cores at the top level contained tumour-adjacent stroma than at 
other levels, though the median cytokeratin-positive area per core at the top level was 
not drastically different to any other TMA depth (Table 5.4). Repeating our analysis 
by reclassifying CD8+ cell scores by proximity to tumour, may address whether such 
a method overcomes the problem of inconsistency we observed at different TMA 
depths. 
Another possible explanation for the inconsistency lies in the number of cores 
selected per patient when constructing the array. Previous studies recommend that 
the number of cores be selected based on the heterogeneity of the tumour being 
studied, with analyses of colorectal, lung and prostate cancer TMAs concluding that 
3-4 cores are optimal150–153. Given the heterogeneity of stromal components noted in 
this study, a similar analysis for PDAC may be warranted, testing core numbers in 
excess of the three used for our TMAs to see if more consistent conclusions can be 
reached at different depths. 
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In summary, we aimed to identify diagnostic markers in the serum of pancreatic 
cancer patients and relate this to expression in the pancreas microenvironment. I have 
identified a candidate biomarker that can distinguish patients with PDAC from 
chronic pancreatitis, and have discovered a potential mechanism to explain this based 
on expression in the tissue microenvironment. I have helped to validate a promising 
biomarker for the early diagnosis of PDAC, both in human and murine samples, and 
compared different methods of quantifying proteins in the serum. From there I 
investigated whether tissue microarrays are appropriate for quantifying components 
of the pancreatic tumour stroma, concluding that caution should be taken when 
comparing the abundance of stromal elements with clinical outcome. Instead, 
quantifying in relation to other features of the microenvironment may be required. 
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